

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-36794



**The Chemours Company**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other Jurisdiction of  
Incorporation or Organization)

**46-4845564**

(I.R.S. Employer  
Identification No.)

**1007 Market Street, Wilmington, Delaware 19801**

(Address of Principal Executive Offices)

**(302) 773-1000**

(Registrant's Telephone Number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Non-Accelerated Filer

Accelerated Filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of Each Class</b>	<b>Trading Symbol(s)</b>	<b>Name of Exchange on Which Registered</b>
Common Stock (\$.01 par value)	CC	New York Stock Exchange

The registrant had 163,481,966 shares of common stock, \$0.01 par value, outstanding at July 29, 2019.

	<u>Page</u>
<b>Part I</b>	
	<b><u>Financial Information</u></b>
Item 1.	<u>Interim Consolidated Financial Statements</u>
	<u>Interim Consolidated Statements of Operations (Unaudited)</u>
	<u>Interim Consolidated Statements of Comprehensive Income (Unaudited)</u>
	<u>Interim Consolidated Balance Sheets</u>
	<u>Interim Consolidated Statements of Stockholders' Equity (Unaudited)</u>
	<u>Interim Consolidated Statements of Cash Flows (Unaudited)</u>
	<u>Notes to the Interim Consolidated Financial Statements (Unaudited)</u>
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>
Item 3.	<u>Quantitative and Qualitative Disclosures About Market Risk</u>
Item 4.	<u>Controls and Procedures</u>
<b>Part II</b>	
	<b><u>Other Information</u></b>
Item 1.	<u>Legal Proceedings</u>
Item 1A.	<u>Risk Factors</u>
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>
Item 3.	<u>Defaults Upon Senior Securities</u>
Item 4.	<u>Mine Safety Disclosures</u>
Item 5.	<u>Other Information</u>
Item 6.	<u>Exhibits</u>
<b><u>Signature</u></b>	

## PART I. FINANCIAL INFORMATION

## Item 1. INTERIM CONSOLIDATED FINANCIAL STATEMENTS

**The Chemours Company**  
**Interim Consolidated Statements of Operations (Unaudited)**  
*(Dollars in millions, except per share amounts)*

	Three Months Ended June 30,		Six Months Ended June 30,	
	2019	2018	2019	2018
Net sales	\$ 1,408	\$ 1,816	\$ 2,784	\$ 3,546
Cost of goods sold	1,085	1,259	2,165	2,452
Gross profit	323	557	619	1,094
Selling, general, and administrative expense	136	161	292	304
Research and development expense	19	20	41	40
Restructuring, asset-related, and other charges	7	10	15	20
Total other operating expenses	162	191	348	364
Equity in earnings of affiliates	8	10	16	22
Interest expense, net	(52)	(48)	(103)	(100)
Loss on extinguishment of debt	—	(38)	—	(38)
Other income, net	16	33	55	90
<b>Income before income taxes</b>	<b>133</b>	<b>323</b>	<b>239</b>	<b>704</b>
Provision for income taxes	37	41	50	125
<b>Net income</b>	<b>96</b>	<b>282</b>	<b>189</b>	<b>579</b>
Less: Net income attributable to non-controlling interests	—	1	—	1
<b>Net income attributable to Chemours</b>	<b>\$ 96</b>	<b>\$ 281</b>	<b>\$ 189</b>	<b>\$ 578</b>
<b>Per share data</b>				
Basic earnings per share of common stock	\$ 0.58	\$ 1.58	\$ 1.14	\$ 3.21
Diluted earnings per share of common stock	0.57	1.53	1.12	3.11

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Interim Consolidated Statements of Comprehensive Income (Unaudited)**  
(Dollars in millions)

	Three Months Ended June 30,					
	2019			2018		
	Pre-tax	Tax	After-tax	Pre-tax	Tax	After-tax
<b>Net income</b>	\$ 133	\$ (37)	\$ 96	\$ 323	\$ (41)	\$ 282
Other comprehensive income (loss):						
Hedging activities:						
Unrealized (loss) gain on net investment hedge	(7)	2	(5)	48	(12)	36
Unrealized gain on cash flow hedge	—	—	—	7	(1)	6
Reclassifications to net income - cash flow hedge	(3)	—	(3)	—	—	—
Hedging activities, net	(10)	2	(8)	55	(13)	42
Cumulative translation adjustment	15	—	15	(160)	—	(160)
Defined benefit plans:						
Additions to accumulated other comprehensive loss:						
Net loss	(3)	—	(3)	—	—	—
Prior service benefit	5	—	5	—	—	—
Effect of foreign exchange rates	(2)	—	(2)	13	—	13
Reclassifications to net income:						
Amortization of prior service gain	(1)	—	(1)	(1)	—	(1)
Amortization of actuarial loss	7	(1)	6	4	—	4
Defined benefit plans, net	6	(1)	5	16	—	16
<b>Other comprehensive income (loss)</b>	11	1	12	(89)	(13)	(102)
<b>Comprehensive income</b>	144	(36)	108	234	(54)	180
Less: Comprehensive income attributable to non-controlling interests	—	—	—	1	—	1
<b>Comprehensive income attributable to Chemours</b>	\$ 144	\$ (36)	\$ 108	\$ 233	\$ (54)	\$ 179

	Six Months Ended June 30,					
	2019			2018		
	Pre-tax	Tax	After-tax	Pre-tax	Tax	After-tax
<b>Net income</b>	\$ 239	\$ (50)	\$ 189	\$ 704	\$ (125)	\$ 579
Other comprehensive income (loss):						
Hedging activities:						
Unrealized gain on net investment hedge	3	(1)	2	13	(3)	10
Unrealized gain on cash flow hedge	2	—	2	7	(1)	6
Reclassifications to net income - cash flow hedge	(6)	—	(6)	—	—	—
Hedging activities, net	(1)	(1)	(2)	20	(4)	16
Cumulative translation adjustment	23	—	23	(53)	—	(53)
Defined benefit plans:						
Additions to accumulated other comprehensive loss:						
Net loss	(3)	—	(3)	—	—	—
Prior service benefit	5	—	5	—	—	—
Effect of foreign exchange rates	1	—	1	5	—	5
Reclassifications to net income:						
Amortization of prior service gain	(1)	—	(1)	(1)	—	(1)
Amortization of actuarial loss	12	(3)	9	7	(1)	6
Settlement loss	1	—	1	—	—	—
Defined benefit plans, net	15	(3)	12	11	(1)	10
<b>Other comprehensive income (loss)</b>	37	(4)	33	(22)	(5)	(27)
<b>Comprehensive income</b>	276	(54)	222	682	(130)	552
Less: Comprehensive income attributable to non-controlling interests	—	—	—	1	—	1
<b>Comprehensive income attributable to Chemours</b>	\$ 276	\$ (54)	\$ 222	\$ 681	\$ (130)	\$ 551

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Interim Consolidated Balance Sheets**  
(Dollars in millions, except per share amounts)

	(Unaudited) June 30, 2019	December 31, 2018
<b>Assets</b>		
Current assets:		
Cash and cash equivalents	\$ 630	\$ 1,201
Accounts and notes receivable, net	879	861
Inventories	1,250	1,147
Prepaid expenses and other	73	84
Total current assets	2,832	3,293
Property, plant, and equipment	9,259	8,992
Less: Accumulated depreciation	(5,768)	(5,701)
Property, plant, and equipment, net	3,491	3,291
Operating lease right-of-use assets	322	—
Goodwill and other intangible assets, net	178	181
Investments in affiliates	177	160
Other assets	433	437
<b>Total assets</b>	<b>\$ 7,433</b>	<b>\$ 7,362</b>
<b>Liabilities</b>		
Current liabilities:		
Accounts payable	\$ 956	\$ 1,137
Current maturities of long-term debt	18	13
Other accrued liabilities	474	559
Total current liabilities	1,448	1,709
Long-term debt, net	4,190	3,959
Operating lease liabilities	265	—
Deferred income taxes	214	217
Other liabilities	487	457
Total liabilities	6,604	6,342
Commitments and contingent liabilities		
<b>Equity</b>		
Common stock (par value \$0.01 per share; 810,000,000 shares authorized; 188,801,201 shares issued and 163,481,966 shares outstanding at June 30, 2019; 187,204,567 shares issued and 170,780,474 shares outstanding at December 31, 2018)	2	2
Treasury stock, at cost (25,319,235 shares at June 30, 2019; 16,424,093 shares at December 31, 2018)	(1,072)	(750)
Additional paid-in capital	853	860
Retained earnings	1,571	1,466
Accumulated other comprehensive loss	(531)	(564)
Total Chemours stockholders' equity	823	1,014
Non-controlling interests	6	6
Total equity	829	1,020
<b>Total liabilities and equity</b>	<b>\$ 7,433</b>	<b>\$ 7,362</b>

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Interim Consolidated Statements of Stockholders' Equity (Unaudited)**  
*(Dollars in millions, except per share amounts)*

	Three Months Ended June 30,									
	Common Stock		Treasury Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Non-controlling Interests	Total Equity	
	Shares	Amount	Shares	Amount						
<b>Balance at April 1, 2018</b>	185,903,112	\$ 2	7,365,558	\$ (361)	\$ 846	\$ 876	\$ (366)	\$ 5	\$ 1,002	
Common stock issued - compensation plans	69,089	—	—	—	—	—	—	—	—	
Exercise of stock options, net	622,167	—	—	—	8	—	—	—	8	
Purchases of treasury stock, at cost	—	—	2,720,089	(139)	—	—	—	—	(139)	
Shares issued under employee stock purchase plan	—	—	(12,411)	—	—	—	—	—	—	
Stock-based compensation expense	—	—	—	—	6	—	—	—	6	
Cancellation of unissued stock awards withheld to cover taxes	—	—	—	—	(1)	—	—	—	(1)	
Net income	—	—	—	—	—	281	—	1	282	
Dividends (\$0.17 per share)	—	—	—	—	—	(30)	—	—	(30)	
Other comprehensive loss	—	—	—	—	—	—	(102)	—	(102)	
Other activity, net	—	—	—	—	—	—	(1)	—	(1)	
<b>Balance at June 30, 2018</b>	<u>186,594,368</u>	<u>\$ 2</u>	<u>10,073,236</u>	<u>\$ (500)</u>	<u>\$ 859</u>	<u>\$ 1,127</u>	<u>\$ (469)</u>	<u>\$ 6</u>	<u>\$ 1,025</u>	
<b>Balance at April 1, 2019</b>	188,693,084	\$ 2	23,702,095	\$ (1,011)	\$ 845	\$ 1,517	\$ (543)	\$ 6	\$ 816	
Common stock issued - compensation plans	13,505	—	—	—	—	—	—	—	—	
Exercise of stock options, net	94,612	—	—	—	2	—	—	—	2	
Purchases of treasury stock, at cost	—	—	1,617,140	(61)	—	—	—	—	(61)	
Stock-based compensation expense	—	—	—	—	6	—	—	—	6	
Cancellation of unissued stock awards withheld to cover taxes	—	—	—	—	—	—	—	—	—	
Net income	—	—	—	—	—	96	—	—	96	
Dividends (\$0.25 per share)	—	—	—	—	—	(42)	—	—	(42)	
Other comprehensive income	—	—	—	—	—	—	12	—	12	
<b>Balance at June 30, 2019</b>	<u>188,801,201</u>	<u>\$ 2</u>	<u>25,319,235</u>	<u>\$ (1,072)</u>	<u>\$ 853</u>	<u>\$ 1,571</u>	<u>\$ (531)</u>	<u>\$ 6</u>	<u>\$ 829</u>	
	Six Months Ended June 30,									
	Common Stock		Treasury Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Non-controlling Interests	Total Equity	
	Shares	Amount	Shares	Amount						
<b>Balance at January 1, 2018</b>	185,343,034	\$ 2	2,386,406	\$ (116)	\$ 837	\$ 579	\$ (442)	\$ 5	\$ 865	
Common stock issued - compensation plans	355,707	—	—	—	—	—	—	—	—	
Exercise of stock options, net	895,627	—	—	—	13	—	—	—	13	
Purchases of treasury stock, at cost	—	—	7,699,241	(384)	—	—	—	—	(384)	
Shares issued under employee stock purchase plan	—	—	(12,411)	—	—	—	—	—	—	
Stock-based compensation expense	—	—	—	—	15	—	—	—	15	
Cancellation of unissued stock awards withheld to cover taxes	—	—	—	—	(6)	—	—	—	(6)	
Net income	—	—	—	—	—	578	—	1	579	
Dividends (\$0.17 per share)	—	—	—	—	—	(30)	—	—	(30)	
Other comprehensive loss	—	—	—	—	—	—	(27)	—	(27)	
<b>Balance at June 30, 2018</b>	<u>186,594,368</u>	<u>\$ 2</u>	<u>10,073,236</u>	<u>\$ (500)</u>	<u>\$ 859</u>	<u>\$ 1,127</u>	<u>\$ (469)</u>	<u>\$ 6</u>	<u>\$ 1,025</u>	
<b>Balance at January 1, 2019</b>	187,204,567	\$ 2	16,424,093	\$ (750)	\$ 860	\$ 1,466	\$ (564)	\$ 6	\$ 1,020	
Common stock issued - compensation plans	1,091,539	—	—	—	1	(1)	—	—	—	
Exercise of stock options, net	505,095	—	—	—	8	—	—	—	8	
Purchases of treasury stock, at cost	—	—	8,895,142	(322)	—	—	—	—	(322)	
Stock-based compensation expense	—	—	—	—	14	—	—	—	14	
Cancellation of unissued stock awards withheld to cover taxes	—	—	—	—	(30)	—	—	—	(30)	
Net income	—	—	—	—	—	189	—	—	189	
Dividends (\$0.50 per share)	—	—	—	—	—	(83)	—	—	(83)	
Other comprehensive income	—	—	—	—	—	—	33	—	33	
<b>Balance at June 30, 2019</b>	<u>188,801,201</u>	<u>\$ 2</u>	<u>25,319,235</u>	<u>\$ (1,072)</u>	<u>\$ 853</u>	<u>\$ 1,571</u>	<u>\$ (531)</u>	<u>\$ 6</u>	<u>\$ 829</u>	

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Interim Consolidated Statements of Cash Flows (Unaudited)**  
(Dollars in millions)

	Six Months Ended June 30,	
	2019	2018
<b>Cash flows from operating activities</b>		
Net income	\$ 189	\$ 579
Adjustments to reconcile net income to cash (used for) provided by operating activities:		
Depreciation and amortization	154	142
Gain on sales of assets and businesses	(3)	(45)
Equity in earnings of affiliates, net	(15)	6
Loss on extinguishment of debt	—	38
Amortization of debt issuance costs and issue discounts	5	7
Deferred tax provision	2	38
Stock-based compensation expense	14	15
Net periodic pension cost (income)	1	(7)
Defined benefit plan contributions	(13)	(8)
Other operating charges and credits, net	1	(5)
Decrease (increase) in operating assets:		
Accounts and notes receivable, net	(16)	(175)
Inventories and other operating assets	(70)	(74)
(Decrease) increase in operating liabilities:		
Accounts payable and other operating liabilities	(287)	28
Cash (used for) provided by operating activities	(38)	539
<b>Cash flows from investing activities</b>		
Purchases of property, plant, and equipment	(257)	(228)
Acquisition of business, net	—	(37)
Proceeds from sales of assets and businesses, net	1	41
Foreign exchange contract settlements, net	—	(6)
Cash used for investing activities	(256)	(230)
<b>Cash flows from financing activities</b>		
Proceeds from issuance of debt, net	—	520
Proceeds from revolving loan	150	—
Debt repayments	(6)	(672)
Payments related to extinguishment of debt	—	(29)
Payments of debt issuance costs	—	(12)
Purchases of treasury stock, at cost	(322)	(394)
Proceeds from exercised stock options, net	8	13
Payments related to tax withholdings on vested stock awards	(30)	(6)
Payments of dividends	(83)	(61)
Cash used for financing activities	(283)	(641)
Effect of exchange rate changes on cash and cash equivalents	6	(7)
<b>Decrease in cash and cash equivalents</b>	(571)	(339)
<b>Cash and cash equivalents at January 1,</b>	1,201	1,556
<b>Cash and cash equivalents at June 30,</b>	\$ 630	\$ 1,217
<b>Supplemental cash flows information</b>		
Non-cash investing and financing activities:		
Changes in property, plant, and equipment included in accounts payable	\$ (25)	\$ (1)
Obligations incurred under build-to-suit lease arrangement	30	26

*See accompanying notes to the interim consolidated financial statements.*

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 1. Background, Description of the Business, and Basis of Presentation**

The Chemours Company (“Chemours,” or “the Company”) is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. The Company delivers customized solutions with a wide range of industrial and specialty chemical products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. The Company’s principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide (“TiO<sub>2</sub>”) pigment. Chemours’ business consists of three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications. The Titanium Technologies segment is a leading, global provider of TiO<sub>2</sub> pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

Chemours separated from E. I. du Pont de Nemours and Company (“DuPont”) on July 1, 2015. On August 31, 2017, DuPont completed a merger with The Dow Chemical Company (“Dow”). Following their merger, DuPont and Dow engaged in a series of reorganization steps and in 2019 have now separated into three publicly-traded companies named Dow Inc., DuPont de Nemours, Inc., and Corteva, Inc. (“Corteva”).

Unless the context otherwise requires, references herein to “The Chemours Company,” “Chemours,” “the Company,” “our Company,” “we,” “us,” and “our” refer to The Chemours Company and its consolidated subsidiaries. References to “DuPont” refer to E. I. du Pont de Nemours and Company, which is now a subsidiary of Corteva.

The accompanying interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). In the opinion of management, all adjustments (consisting of normal, recurring adjustments) considered necessary for a fair statement of the Company’s results for interim periods have been included. The notes that follow are an integral part of the Company’s interim consolidated financial statements. The Company’s results for interim periods should not be considered indicative of its results for a full year, and the year-end consolidated balance sheet does not include all of the disclosures required by GAAP. As such, these interim consolidated financial statements should be read in conjunction with the *Consolidated Financial Statements* and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018.

Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which, was not material to the Company’s interim consolidated financial statements.

**Note 2. Recent Accounting Pronouncements**

***Accounting Guidance Issued and Not Yet Adopted***

***Changes to Disclosure Requirements for Defined Benefit Plans***

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-14, *Compensation – Retirement Benefits – Defined Benefit Plans – General (Subtopic 715-20): Disclosure Framework – Changes to the Disclosure Requirements for Defined Benefit Plans* (“ASU No. 2018-14”). This update removes disclosures that are no longer considered cost beneficial, clarifies the specific requirements of certain disclosures, and adds new disclosure requirements that are considered relevant for employers that sponsor defined benefit pension or other postretirement plans. ASU No. 2018-14 is effective for fiscal years ending after December 15, 2020 with retrospective application to all periods presented, and early adoption is permitted. The Company is currently evaluating the impacts of adopting this guidance, which it does not expect to be material.

***Recently Adopted Accounting Guidance***

***Leases***

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)* (“ASU No. 2016-02”), which supersedes the leases requirements in Topic 840. The core principle of ASU No. 2016-02 is that a lessee should recognize on the balance sheet the lease assets and lease liabilities that arise from all lease arrangements with terms greater than 12 months. Recognition of these lease assets and lease liabilities represents a change from previous GAAP, which did not require lease assets and lease liabilities to be recognized for operating leases.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The Company adopted ASU No. 2016-02 on January 1, 2019 using the modified retrospective transition method, which did not require the Company to adjust comparative periods. Operating leases are included in operating lease right-of-use assets, other accrued liabilities, and operating lease liabilities on the consolidated balance sheets. Finance leases are included in property, plant, and equipment, net, current maturities of long-term debt, and long-term debt, net, on the consolidated balance sheets. The Company's lease assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments. The Company's incremental borrowing rate, which is based on information available at the adoption date for existing leases and the commencement date for leases commencing after the adoption date, is used to determine the present value of lease payments.

The most significant impact of the Company's adoption of ASU No. 2016-02 was the recognition of \$333 of operating lease right-of-use assets and \$349 of operating lease liabilities on its consolidated balance sheets at January 1, 2019. Operating lease right-of-use assets were reduced by \$16 due to a tenant improvement allowance on a lease of office space. The Company's adoption of ASU No. 2016-02 did not have any impact to the Company's consolidated statements of operations, or its consolidated statements of cash flows. Further, there was no impact on the Company's covenant compliance under its current debt agreements as a result of the adoption of ASU No. 2016-02.

The Company elected the package of practical expedients included in this guidance, which allowed it to not reassess: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and, (iii) the initial direct costs for existing leases. The Company also elected the practical expedient to not assess whether existing or expired land easements contain a lease.

The Company does not recognize short-term leases on its consolidated balance sheets, and will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. Leases with the options to extend their term or terminate early are reflected in the lease term when it is reasonably certain that the Company will exercise such options.

*Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*

In August 2018, the FASB issued ASU No. 2018-15, *Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract* ("ASU No. 2018-15"), which aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Pursuant to the amendments, the Company, when acting as a customer to a cloud computing arrangement that is a service contract, is required to follow the guidance in Subtopic 350-40 to determine the implementation costs to capitalize as an asset related to the service contract and the costs to expense. ASU No. 2018-15 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted in any interim period. Upon adoption, the Company had the option to elect whether it applies the amendments under ASU No. 2018-15 retrospectively, or prospectively to all implementation costs incurred after the date of adoption. The Company adopted ASU No. 2018-15 on January 1, 2019 using the prospective adoption method, the effect of which, was not material to its financial position, results of operations, or cash flows for the six months ended June 30, 2019.

**Note 3. Significant Transaction**

***Sale of Land in Linden, New Jersey***

In March 2016, the Company entered into an agreement to sell a 210-acre plot of land that formerly housed a DuPont manufacturing site in Linden, New Jersey. The land was assigned to Chemours in connection with its separation from DuPont, and the Company completed the sale in March 2018 for a gain of \$42 and net cash proceeds of \$39. As part of the sales agreement, the buyer agreed to assume certain costs associated with ongoing environmental remediation activities at the site amounting to \$3, which have been reflected as a component of prepaid expenses and other on the consolidated balance sheets. Chemours remains responsible for certain other ongoing environmental remediation activities at the site, which were previously accrued as a component of other liabilities on the consolidated balance sheets.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 4. Net Sales**

**Disaggregation of Net Sales**

The following table sets forth a disaggregation of the Company's net sales by geographic region and product group for the three and six months ended June 30, 2019 and 2018.

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<b>Net sales by geographic region (1)</b>				
North America:				
Fluoroproducts	\$ 305	\$ 310	\$ 592	\$ 613
Chemical Solutions	85	90	159	172
Titanium Technologies	176	239	372	472
Total North America	<u>566</u>	<u>639</u>	<u>1,123</u>	<u>1,257</u>
Asia Pacific:				
Fluoroproducts	175	186	338	338
Chemical Solutions	16	21	31	41
Titanium Technologies	195	260	362	503
Total Asia Pacific	<u>386</u>	<u>467</u>	<u>731</u>	<u>882</u>
Europe, the Middle East, and Africa:				
Fluoroproducts	178	249	364	471
Chemical Solutions	4	5	10	9
Titanium Technologies	123	245	237	492
Total Europe, the Middle East, and Africa	<u>305</u>	<u>499</u>	<u>611</u>	<u>972</u>
Latin America (2):				
Fluoroproducts	54	56	104	110
Chemical Solutions	25	37	64	75
Titanium Technologies	72	118	151	250
Total Latin America	<u>151</u>	<u>211</u>	<u>319</u>	<u>435</u>
<b>Total net sales</b>	<u>\$ 1,408</u>	<u>\$ 1,816</u>	<u>\$ 2,784</u>	<u>\$ 3,546</u>
<b>Net sales by product group</b>				
Fluorochemicals	\$ 375	\$ 444	\$ 724	\$ 838
Fluoropolymers	336	357	674	694
Mining solutions	61	71	130	137
Performance chemicals and intermediates	69	82	134	160
Titanium dioxide and other minerals	567	862	1,122	1,717
<b>Total net sales</b>	<u>\$ 1,408</u>	<u>\$ 1,816</u>	<u>\$ 2,784</u>	<u>\$ 3,546</u>

(1) Net sales are attributed to countries based on customer location.

(2) Latin America includes Mexico.

Substantially all of the Company's net sales are derived from goods and services transferred at a point in time.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Contract Balances**

The Company's assets and liabilities from contracts with customers constitute accounts receivable - trade, deferred revenue, and customer rebates. An amount for accounts receivable - trade is recorded when the right to consideration under a contract becomes unconditional. An amount for deferred revenue is recorded when consideration is received prior to the conclusion that a contract exists, or when a customer transfers consideration prior to the Company satisfying its performance obligations under a contract. Customer rebates represent an expected refund liability to a customer based on a contract. In contracts with customers where a rebate is offered, it is generally applied retroactively based on the achievement of a certain sales threshold. As revenue is recognized, the Company estimates whether or not the sales threshold will be achieved to determine the amount of variable consideration to include in the transaction price.

The following table sets forth the Company's contract balances from contracts with customers at June 30, 2019 and December 31, 2018.

	<b>June 30, 2019</b>		<b>December 31, 2018</b>	
Accounts receivable - trade, net (1)	\$	808	\$	790
Customer rebates		51		79

(1) Accounts receivable - trade, net includes trade notes receivable of \$2 and is net of allowances for doubtful accounts of \$5 at June 30, 2019 and December 31, 2018. Such allowances are equal to the estimated uncollectible amounts.

The Company's deferred revenue balances at June 30, 2019 and December 31, 2018 were not significant. Additionally, changes in the Company's deferred revenue balances resulting from additions for advance payments and deductions for amounts recognized in net sales during the three and six months ended June 30, 2019 were not significant. For the three and six months ended June 30, 2019, the amount of net sales recognized from performance obligations satisfied in prior periods (e.g., due to changes in transaction price) was not significant.

There were no other contract asset balances or capitalized costs associated with obtaining or fulfilling customer contracts as of June 30, 2019 or December 31, 2018.

**Remaining Performance Obligations**

Certain of the Company's master services agreements or other arrangements contain take-or-pay clauses, whereby customers are required to purchase a fixed minimum quantity of product during a specified period, or pay the Company for such orders, even if not requested by the customer. The Company considers these take-or-pay clauses to be an enforceable contract, and as such, the legally-enforceable minimum amounts under such an arrangement are considered to be outstanding performance obligations on contracts with an original expected duration greater than one year. At June 30, 2019, Chemours had \$117 of remaining performance obligations. The Company expects to recognize approximately 30% of its remaining performance obligations as revenue in 2019, an approximate additional 50% in 2020, and the balance thereafter. The Company applies the allowable practical expedient and does not include remaining performance obligations that have original expected durations of one year or less, or amounts for variable consideration allocated to wholly-unsatisfied performance obligations or wholly-unsatisfied distinct goods that form part of a single performance obligation, if any. Amounts for contract renewals that are not yet exercised by June 30, 2019 are also excluded.

**Note 5. Restructuring, Asset-related, and Other Charges**

The following table sets forth the components of the Company's restructuring, asset-related, and other charges for the three and six months ended June 30, 2019 and 2018.

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Restructuring and other charges:				
Employee separation charges	\$ —	\$ 3	\$ —	\$ 6
Decommissioning and other charges	7	6	15	13
Total restructuring and other charges	7	9	15	19
Asset-related and other charges	—	1	—	1
<b>Total restructuring, asset-related, and other charges</b>	<b>\$ 7</b>	<b>\$ 10</b>	<b>\$ 15</b>	<b>\$ 20</b>

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The following table sets forth the impacts of the Company's restructuring programs to segment earnings for the three and six months ended June 30, 2019 and 2018.

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<b>Restructuring and other charges:</b>				
Plant and product line closures:				
Chemical Solutions	\$ —	\$ 2	\$ 1	\$ 3
Corporate and Other	6	1	12	1
Total plant and product line closures	6	3	13	4
2017 Restructuring Program:				
Fluoroproducts	1	2	1	5
Chemical Solutions	—	1	—	1
Titanium Technologies	1	—	1	—
Corporate and Other	(1)	3	—	9
Total 2017 Restructuring Program	1	6	2	15
<b>Total restructuring and other charges</b>	<b>\$ 7</b>	<b>\$ 9</b>	<b>\$ 15</b>	<b>\$ 19</b>

**Plant and Product Line Closures**

In the fourth quarter of 2015, the Company announced its completion of the strategic review of its Reactive Metals Solutions business and the decision to stop production at its Niagara Falls, New York manufacturing plant. The Company recorded additional decommissioning and dismantling-related charges of \$1 for the six months ended June 30, 2019, and \$2 and \$3 for the three and six months ended June 30, 2018, respectively. The Company expects to incur approximately \$10 in additional restructuring charges for similar activities through 2021, which will be reflected in Chemical Solutions, and will be expensed as incurred. As of June 30, 2019, the Company incurred, in the aggregate, \$36 in restructuring charges related to these activities, excluding asset-related charges.

In the first quarter of 2018, the Company began a project to demolish and remove several dormant, unused buildings at its Chambers Works site in Deepwater, New Jersey, which were assigned to Chemours in connection with its separation from DuPont and never used in Chemours' operations. The Company recorded additional decommissioning and dismantling-related charges of \$6 and \$12 for the three and six months ended June 30, 2019, respectively, and \$1 for the three and six months ended June 30, 2018. The Company expects to incur approximately \$10 in additional restructuring charges related to its Chambers Works site through the end of 2020, which will be reflected in Corporate and Other, and will be expensed as incurred. As of June 30, 2019, the Company incurred, in the aggregate, \$21 in restructuring charges related to these activities.

**2017 Restructuring Program**

In 2017, the Company announced certain restructuring activities designed to further the cost savings and productivity improvements outlined under management's transformation plan. These activities include, among other efforts: (i) outsourcing and further centralizing certain business process activities; (ii) consolidating existing, outsourced third-party information technology ("IT") providers; and, (iii) implementing various upgrades to the Company's current IT infrastructure. In connection with these corporate function efforts, the Company recorded \$1 and \$2 in restructuring-related charges for the three and six months ended June 30, 2019, respectively, and \$3 and \$9 for the three and six months ended June 30, 2018, respectively.

In 2017, the Company also announced a voluntary separation program ("VSP") for certain eligible U.S. employees in an effort to better manage the anticipated future changes to its workforce. Employees who volunteered for and were accepted under the VSP received certain financial incentives above the Company's customary involuntary termination benefits to end their employment with Chemours after providing a mutually agreed-upon service period. Approximately 300 employees separated from the Company through the end of 2018. An accrual representing the majority of these termination benefits, amounting to \$18, was recognized in the fourth quarter of 2017. The remaining incremental, one-time financial incentives under the VSP were recognized over the period that each participating employee continued to provide service to Chemours, and amounted to \$3 and \$6 for the three and six months ended June 30, 2018, respectively.

The Company recorded charges for its 2017 program of \$1 and \$2 during the three and six months ended June 30, 2019, respectively, and \$6 and \$15 during the three and six months ended June 30, 2018, respectively. The cumulative amount incurred, in the aggregate, for the Company's 2017 program amounted to \$61 at June 30, 2019. The Company has substantially completed all actions related to this program.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**2018 Restructuring Program**

In the fourth quarter of 2018, management initiated a restructuring program of the Company's corporate functions and recorded the related estimated severance costs of \$5. The Company has substantially completed all actions related to this program.

The following table sets forth the change in the Company's employee separation-related liabilities associated with its restructuring programs for the six months ended June 30, 2019.

	2015 Global Restructuring Program	2017 Restructuring Program	2018 Restructuring Program	Total
<b>Balance at December 31, 2018</b>	\$ 1	\$ 10	\$ 5	\$ 16
Credits to income	(1)	—	—	(1)
Payments	—	(9)	(4)	(13)
<b>Balance at June 30, 2019</b>	<u>\$ —</u>	<u>\$ 1</u>	<u>\$ 1</u>	<u>\$ 2</u>

At June 30, 2019, there were no significant outstanding liabilities related to the Company's decommissioning and other restructuring-related charges.

**Note 6. Other Income, Net**

The following table sets forth the components of the Company's other income, net for the three and six months ended June 30, 2019 and 2018.

	Three Months Ended June 30,		Six Months Ended June 30,	
	2019	2018	2019	2018
Leasing, contract services, and miscellaneous income (1)	\$ 16	\$ 20	\$ 41	\$ 22
Royalty income (2)	4	1	9	7
Gain on sales of assets and businesses (3)	2	3	2	45
Exchange (losses) gains, net (4)	(9)	2	(3)	2
Non-operating pension and other post-retirement employee benefit income	3	7	6	14
<b>Total other income, net</b>	<u>\$ 16</u>	<u>\$ 33</u>	<u>\$ 55</u>	<u>\$ 90</u>

(1) Leasing, contract services, and miscellaneous income includes European Union fluorinated greenhouse gas quota authorization sales of \$12 and \$36 for the three and six months ended June 30, 2019, respectively, and \$18 and \$20 for the three and six months ended June 30, 2018, respectively.

(2) Royalty income is primarily from technology licensing.

(3) For the six months ended June 30, 2018, gain on sales of assets and businesses included a \$42 gain associated with the sale of the Company's Linden, New Jersey site.

(4) Exchange (losses) gains, net includes gains and losses on foreign currency forward contracts.

**Note 7. Income Taxes**

For the three months ended June 30, 2019 and 2018, Chemours recorded provisions for income taxes of \$37 and \$41, respectively, resulting in effective income tax rates of approximately 28% and 13%, respectively. The change in the Company's effective tax rate for the three months ended June 30, 2019 was primarily attributable to \$6 of lower income tax benefits related to windfalls on its share-based payments, \$8 of additional income tax expense associated with the recognition of a valuation allowance on the deferred tax assets of a certain foreign subsidiary, and the geographic mix of its earnings.

For the six months ended June 30, 2019 and 2018, Chemours recorded provisions for income taxes of \$50 and \$125, respectively, resulting in effective income tax rates of approximately 21% and 18%, respectively. The change in the Company's effective tax rate for the six months ended June 30, 2019 was primarily attributable to \$4 of lower income tax benefits related to windfalls on its share-based payments, \$8 of additional income tax expense associated with the recognition of a valuation allowance on the deferred tax assets of a certain foreign subsidiary, and the geographic mix of its earnings.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

With respect to U.S. tax reform, while management has completed its analysis within the applicable measurement period, pursuant to the U.S. Securities and Exchange Commission’s Staff Accounting Bulletin No. 118, the Company is accounting for the tax impact of new provisions based on an interpretation of existing statutory law, including proposed regulations issued by the U.S. Treasury and the Internal Revenue Service. While there can be no assurances as to the effect of any final regulations on the Company’s provision for income taxes, management will continue to evaluate the impact as any regulations issued become final during 2019.

**Note 8. Earnings Per Share of Common Stock**

The following table sets forth the reconciliations of the numerators and denominators for the Company’s basic and diluted earnings per share (“EPS”) calculations for the three and six months ended June 30, 2019 and 2018.

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June 30,</u>	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
<b>Numerator:</b>				
Net income attributable to Chemours	\$ 96	\$ 281	\$ 189	\$ 578
<b>Denominator:</b>				
Weighted-average number of common shares outstanding - basic	164,118,816	177,798,484	165,982,289	179,922,433
Dilutive effect of the Company’s employee compensation plans	<u>2,822,810</u>	<u>6,022,757</u>	<u>3,508,621</u>	<u>6,142,986</u>
Weighted-average number of common shares outstanding - diluted	<u>166,941,626</u>	<u>183,821,241</u>	<u>169,490,910</u>	<u>186,065,419</u>
Basic earnings per share of common stock	\$ 0.58	\$ 1.58	\$ 1.14	\$ 3.21
Diluted earnings per share of common stock	0.57	1.53	1.12	3.11

The following table sets forth the average number of stock options that were anti-dilutive and, therefore, were not included in the Company’s diluted EPS calculations for the three and six months ended June 30, 2019 and 2018.

	<u>Three Months Ended June 30,</u>		<u>Six Months Ended June 30,</u>	
	<u>2019</u>	<u>2018</u>	<u>2019</u>	<u>2018</u>
Average number of stock options	1,800,298	—	1,241,716	—

**Note 9. Accounts and Notes Receivable, Net**

The following table sets forth the components of the Company’s accounts and notes receivable, net at June 30, 2019 and December 31, 2018.

	<u>June 30, 2019</u>	<u>December 31, 2018</u>
Accounts receivable - trade, net (1)	\$ 808	\$ 790
VAT, GST, and other taxes (2)	61	56
Other receivables (3)	10	15
<b>Total accounts and notes receivable, net</b>	<u>\$ 879</u>	<u>\$ 861</u>

- (1) Accounts receivable - trade, net includes trade notes receivable of \$2 and is net of allowances for doubtful accounts of \$5 at June 30, 2019 and December 31, 2018. Such allowances are equal to the estimated uncollectible amounts.
- (2) Value added tax (“VAT”) and goods and services tax (“GST”) for various jurisdictions.
- (3) Other receivables consist of derivative instruments, advances, and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than \$1 for the three and six months ended June 30, 2019 and 2018.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 10. Inventories**

The following table sets forth the components of the Company's inventories at June 30, 2019 and December 31, 2018.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Finished products	\$ 745	\$ 701
Semi-finished products	199	195
Raw materials, stores, and supplies	537	476
Inventories before LIFO adjustment	1,481	1,372
Less: Adjustment of inventories to LIFO basis	(231)	(225)
<b>Total inventories</b>	<b>\$ 1,250</b>	<b>\$ 1,147</b>

Inventory values, before last-in, first-out ("LIFO") adjustment are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the Company's U.S. locations, which comprised \$751 and \$622 (or 51% and 45%) of inventories before the LIFO adjustments at June 30, 2019 and December 31, 2018, respectively. The remainder of the Company's inventory held in international locations and certain U.S. locations is valued under the average cost method.

**Note 11. Property, Plant, and Equipment, Net**

The following table sets forth the components of the Company's property, plant, and equipment, net at June 30, 2019 and December 31, 2018.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Equipment	\$ 7,523	\$ 7,344
Buildings	926	914
Construction-in-progress	661	579
Land	113	119
Mineral rights	36	36
Property, plant, and equipment	9,259	8,992
Less: Accumulated depreciation	(5,768)	(5,701)
<b>Total property, plant, and equipment, net</b>	<b>\$ 3,491</b>	<b>\$ 3,291</b>

Depreciation expense amounted to \$76 and \$151 for the three and six months ended June 30, 2019 and \$70 and \$139 for the three and six months ended June 30, 2018, respectively. Property, plant, and equipment, net includes a build-to-suit lease asset of \$85 and \$55 at June 30, 2019 and December 31, 2018, respectively.

The Company's gross finance lease assets amounted to \$69 and \$7 at June 30, 2019 and December 31, 2018, respectively. In the second quarter of 2019, a subsidiary of the Company renegotiated the terms of an existing Fluoroproducts supply contract with Changshu 3F Zhonghao New Chemical Materials Co., Ltd., a related party and equity method investee, to improve the long-term supply security and competitiveness relative to not-in-kind competition of its low global warming potential foam offering. The renegotiated supply contract resulted in the recognition of a finance lease asset and a corresponding finance lease liability, which amounted to \$62.

**Note 12. Leases**

The Company leases certain office space, equipment, railcars, tanks, barges, tow boats, and warehouses. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets and lease expense is recognized over the term of these leases on a straight-line basis. The Company's leases have remaining terms of up to 18 years. Some leases of equipment contain immaterial amounts of residual value guarantees.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The following table sets forth the Company's lease assets and lease liabilities and their balance sheet location at June 30, 2019.

	<b>Balance Sheet Location</b>	<b>June 30, 2019</b>
<b>Lease assets:</b>		
Operating lease right-of-use assets	Operating lease right-of-use assets	\$ 322
Finance lease assets, net	Property, plant, and equipment, net (Note 11)	64
<b>Total lease assets</b>		<b>\$ 386</b>
<b>Lease liabilities:</b>		
<b>Current:</b>		
Operating lease liabilities	Other accrued liabilities (Note 16)	\$ 74
Finance lease liabilities	Current maturities of long-term debt (Note 17)	5
Total current lease liabilities		79
<b>Non-current:</b>		
Operating lease liabilities	Operating lease liabilities	265
Finance lease liabilities	Long-term debt, net (Note 17)	59
Total non-current lease liabilities		324
<b>Total lease liabilities</b>		<b>\$ 403</b>

The following table sets forth the components of the Company's lease cost for the three and six months ended June 30, 2019.

	<b>Three Months Ended June 30, 2019</b>	<b>Six Months Ended June 30, 2019</b>
Operating lease cost	\$ 24	\$ 49
Short-term lease cost	1	2
Variable lease cost	4	8
<b>Total lease cost</b>	<b>\$ 29</b>	<b>\$ 59</b>

The total cost associated with the Company's finance leases amounted to less than \$1 for the three and six months ended June 30, 2019.

The following table sets forth the cash flows related to the Company's leases for the six months ended June 30, 2019.

	<b>Six Months Ended June 30, 2019</b>
<b>Cash paid for amounts included in the measurement of lease liabilities:</b>	
Operating cash flows from operating leases	\$ 49
<b>Non-cash lease liabilities activity:</b>	
Leased assets obtained in exchange for new operating lease liabilities	\$ 40
Leased assets obtained in exchange for new finance lease liabilities	62

The total cash flows associated with the Company's finance leases amounted to less than \$1 for the six months ended June 30, 2019.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The following table sets forth the weighted-average term and weighted-average discount rate for the Company's leases at June 30, 2019.

	<b>June 30, 2019</b>
Weighted-average remaining lease term (years):	
Operating leases	8.5
Finance leases	9.6
Weighted-average discount rate:	
Operating leases	5.10%
Finance leases	5.90%

The following table sets forth the Company's lease liabilities' maturities for the next five years and thereafter.

	<b>As of June 30, 2019</b>		
	<b>Operating Leases</b>	<b>Finance Leases</b>	<b>Total</b>
Remainder of 2019	\$ 49	\$ 4	\$ 53
2020	77	10	87
2021	67	8	75
2022	48	8	56
2023	32	8	40
Thereafter	147	45	192
Total lease payments	420	83	503
Less: Imputed interest	81	19	100
<b>Present value of lease liabilities</b>	<b>\$ 339</b>	<b>\$ 64</b>	<b>\$ 403</b>

The following table sets forth the Company's lease liabilities' maturities for the next five years and thereafter under the previous lease accounting standard.

	<b>As of December 31, 2018</b>		
	<b>Operating Leases</b>	<b>Finance Leases</b>	<b>Total</b>
2019	\$ 92	\$ —	\$ 92
2020	70	2	72
2021	59	—	59
2022	42	—	42
2023	27	—	27
Thereafter	134	—	134
<b>Total lease payments</b>	<b>\$ 424</b>	<b>\$ 2</b>	<b>\$ 426</b>

***Build-to-suit Lease Obligation***

In October 2017, Chemours executed a build-to-suit lease agreement to construct a new 312,000-square-foot research and development facility on the Science, Technology, and Advanced Research campus of the University of Delaware ("UD") in Newark, Delaware ("The Chemours Discovery Hub"). The land on which The Chemours Discovery Hub will be located is leased to a third-party owner-lessor by UD, and Chemours will act as the construction agent and ultimate lessee of the facility based on the Company's agreement with the owner-lessor. Project costs paid by the owner-lessor are reflected on the Company's consolidated balance sheets as construction-in-progress within property, plant, and equipment, net, and a corresponding build-to-suit lease liability within long-term debt, net. Through June 30, 2019 and December 31, 2018, project costs paid by the owner-lessor amounted to \$85 and \$55, respectively. Construction of The Chemours Discovery Hub is expected to be completed by the end of 2019.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 13. Investments in Affiliates**

The Company engages in transactions with its equity method investees in the ordinary course of business. Net sales to the Company's equity method investees amounted to \$32 and \$64 for the three and six months ended June 30, 2019, respectively, and \$35 and \$63 for the three and six months ended June 30, 2018, respectively. Purchases from the Company's equity method investees amounted to \$41 and \$85 for the three and six months ended June 30, 2019, respectively, and \$31 and \$68 for the three and six months ended June 30, 2018, respectively. The Company also received less than \$1 and \$1 in dividends from its equity method investees for the three and six months ended June 30, 2019, respectively, and less than \$1 and \$28 for the three and six months ended June 30, 2018, respectively.

**Note 14. Other Assets**

The following table sets forth the components of the Company's other assets at June 30, 2019 and December 31, 2018.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Capitalized repair and maintenance costs	\$ 153	\$ 178
Pension assets (1)	193	174
Deferred income taxes	39	46
Miscellaneous	48	39
<b>Total other assets</b>	<b>\$ 433</b>	<b>\$ 437</b>

(1) Pension assets represent the funded status of certain of the Company's long-term employee benefit plans.

**Note 15. Accounts Payable**

The following table sets forth the components of the Company's accounts payable at June 30, 2019 and December 31, 2018.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Trade payables	\$ 929	\$ 1,111
VAT and other payables	27	26
<b>Total accounts payable</b>	<b>\$ 956</b>	<b>\$ 1,137</b>

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 16. Other Accrued Liabilities**

The following table sets forth the components of the Company's other accrued liabilities at June 30, 2019 and December 31, 2018.

	June 30, 2019	December 31, 2018
Compensation and other employee-related costs	\$ 58	\$ 108
Employee separation costs (1)	2	16
Accrued litigation (2)	32	76
Environmental remediation (2)	78	74
Income taxes	57	87
Customer rebates	51	79
Deferred income	8	6
Accrued interest	21	21
Operating lease liabilities (3)	74	—
Miscellaneous (4)	93	92
<b>Total other accrued liabilities</b>	<b>\$ 474</b>	<b>\$ 559</b>

- (1) Represents the current portion of accrued employee separation costs related to the Company's restructuring activities.
- (2) Represents the current portions of accrued litigation and environmental remediation, which are discussed further in "Note 19 – Commitments and Contingent Liabilities."
- (3) Represents the current portion of the Company's operating lease liabilities, which is discussed further in "Note 2 – Recent Accounting Pronouncements" and "Note 12 – Leases."
- (4) Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability, the current portion of the Company's asset retirement obligations, and other miscellaneous expenses.

**Note 17. Debt**

The following table sets forth the components of the Company's debt at June 30, 2019 and December 31, 2018.

	June 30, 2019	December 31, 2018
<b>Senior secured term loans:</b>		
Tranche B-2 U.S. dollar term loan due May 2025	\$ 889	\$ 893
Tranche B-2 euro term loan due May 2025 (€346 at June 30, 2019 and €347 at December 31, 2018)	392	396
Revolving loan (1)	150	—
<b>Senior unsecured notes:</b>		
6.625% due May 2023	908	908
7.000% due May 2025	750	750
4.000% due May 2026 (€450 at June 30, 2019 and December 31, 2018)	511	513
5.375% due May 2027	500	500
Finance lease liabilities	64	2
Build-to-suit lease obligation	85	55
<b>Total debt</b>	<b>4,249</b>	<b>4,017</b>
Less: Unamortized issue discounts	(9)	(10)
Less: Unamortized debt issuance costs	(32)	(35)
Less: Current maturities of long-term debt	(18)	(13)
<b>Total long-term debt, net</b>	<b>\$ 4,190</b>	<b>\$ 3,959</b>

- (1) In July 2019, the Company repaid \$150 of its outstanding revolving loan borrowings using cash from its accounts receivable securitization facility and available cash. See "Note 25 – Subsequent Events" for further information related to the Company's accounts receivable securitization facility.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Senior Secured Credit Facilities**

The Company's credit agreement, as amended, provides for seven-year, senior secured term loans and a five-year, \$800 senior secured revolving credit facility ("Revolving Credit Facility"). The Company had \$150 of outstanding loans under the Revolving Credit Facility at June 30, 2019, which were repaid in full in July 2019. No borrowings were outstanding under the Revolving Credit Facility at December 31, 2018. Chemours also had \$103 and \$104 in letters of credit issued and outstanding under the Revolving Credit Facility at June 30, 2019 and December 31, 2018, respectively. At June 30, 2019, the effective interest rates on the class of term loans denominated in U.S. dollars, the class of term loans denominated in euros, and the revolving loan were 4.16%, 2.50%, and 3.91%, respectively. Also, at June 30, 2019, commitment fees on the Revolving Credit Facility were assessed at a rate of 0.15% per annum.

**Maturities**

The Company has required quarterly principal payments related to its senior secured term loans equivalent to 1.00% per annum through December 2024, with the balance due at maturity. Also, following the end of each fiscal year commencing on the year ended December 31, 2019, on an annual basis, the Company is required to make additional principal payments depending on leverage levels, as defined in the amended and restated credit agreement, equivalent to up to 50% of excess cash flows based on certain leverage targets with step-downs to 25% and 0% as actual leverage decreases to below a 3.50 to 1.00 leverage target.

The following table sets forth the Company's contractual debt principal maturities for the next five years and thereafter.

	<b>Year Ended December 31,</b>
Remainder of 2019	\$ 6
2020	13
2021	13
2022	13
2023	1,071
Thereafter	2,984
<b>Total principal maturities on senior debt</b>	<b>\$ 4,100</b>

The Company's senior secured credit facilities are also subject to a springing maturity in the event that its 6.625% senior unsecured notes due May 2023 are not redeemed, repaid, modified, and/or refinanced within the 91-day period prior to their maturity date.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Debt Fair Value**

The following table sets forth the estimated fair values of the Company's senior debt issues, which are based on quotes received from third-party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy. The carrying value of the revolving loan balance outstanding under the Revolving Credit Facility approximates its fair value due to the frequency at which the interest rate resets.

	June 30, 2019		December 31, 2018	
	Carrying Value	Fair Value	Carrying Value	Fair Value
<b>Senior secured term loans:</b>				
Tranche B-2 U.S. dollar term loan due May 2025	\$ 889	\$ 864	\$ 893	\$ 862
Tranche B-2 euro term loan due May 2025 (€346 at June 30, 2019 and €347 December 31, 2018)	392	394	396	394
Revolving loan	150	150	—	—
<b>Senior unsecured notes:</b>				
6.625% due May 2023	908	942	908	918
7.000% due May 2025	750	784	750	761
4.000% due May 2026 (€450 at June 30, 2019 and December 31, 2018)	511	514	513	487
5.375% due May 2027	500	480	500	454
<b>Total senior debt</b>	<u>4,100</u>	<u>\$ 4,128</u>	<u>3,960</u>	<u>\$ 3,876</u>
Less: Unamortized issue discounts	(9)		(10)	
Less: Unamortized debt issuance costs	(32)		(35)	
<b>Total senior debt, net</b>	<u>\$ 4,059</u>		<u>\$ 3,915</u>	

**Note 18. Other Liabilities**

The following table sets forth the components of the Company's other liabilities at June 30, 2019 and December 31, 2018.

	June 30, 2019	December 31, 2018
Environmental remediation (1)	\$ 166	\$ 152
Employee-related costs (2)	114	130
Accrued litigation (1)	88	53
Asset retirement obligations	51	51
Deferred revenue	5	7
Miscellaneous (3)	63	64
<b>Total other liabilities</b>	<u>\$ 487</u>	<u>\$ 457</u>

- (1) The Company's accrued environmental remediation and accrued litigation liabilities are discussed further in "Note 19 – Commitments and Contingent Liabilities."
- (2) Employee-related costs primarily represent liabilities associated with the Company's long-term employee benefits plans.
- (3) Miscellaneous primarily includes an accrued indemnification liability of \$43 and \$46 at June 30, 2019 and December 31, 2018, respectively.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 19. Commitments and Contingent Liabilities**

**Litigation**

In addition to the matters discussed below, the Company and certain of its subsidiaries, from time to time, are subject to various lawsuits, claims, assessments, and proceedings with respect to product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. In addition, Chemours, by virtue of its status as a subsidiary of DuPont prior to the separation, is subject to or required under the separation-related agreements executed prior to the separation to indemnify DuPont against various pending legal proceedings. It is not possible to predict the outcomes of these various lawsuits, claims, assessments, or proceedings. While management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on the Company's consolidated financial position, results of operations, or cash flows. Additional disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

The Company accrues for litigation matters when it is probable that a liability has been incurred, and the amount of the liability can be reasonably estimated. Legal costs such as outside counsel fees and expenses are recognized in the period in which the expense was incurred. Management believes the Company's litigation liabilities are appropriate based on the facts and circumstances for each matter, which are discussed in further detail below.

The following table sets forth the components of the Company's accrued litigation at June 30, 2019 and December 31, 2018.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Asbestos	\$ 37	\$ 37
Perfluorooctanoic acids and its salts, including the ammonium salt	22	22
GenX and other perfluorinated and polyfluorinated compounds (1)	56	65
All other matters (2)	5	5
<b>Total accrued litigation</b>	<b>\$ 120</b>	<b>\$ 129</b>

- (1) Total accruals related to this matter amounted to \$87 and \$75 at June 30, 2019 and December 31, 2018, respectively. These amounts included \$31 and \$10, which are reflected as a component of the Company's environmental remediation liabilities at June 30, 2019 and December 31, 2018, respectively.
- (2) Includes liabilities related to miscellaneous litigation matters, including Benzene. The Company had accruals related to Benzene of less than \$1 at June 30, 2019. The Company had no accruals related to Benzene at December 31, 2018.

The following table sets forth the current and long-term components of the Company's accrued litigation and their balance sheet locations at June 30, 2019 and December 31, 2018.

	<b>Balance Sheet Location</b>	<b>June 30, 2019</b>	<b>December 31, 2018</b>
<b>Accrued Litigation:</b>			
Current accrued litigation	Other accrued liabilities (Note 16)	\$ 32	\$ 76
Long-term accrued litigation	Other liabilities (Note 18)	88	53
<b>Total accrued litigation</b>		<b>\$ 120</b>	<b>\$ 129</b>

**Asbestos**

In the separation, DuPont assigned its asbestos docket to Chemours. At June 30, 2019 and December 31, 2018, there were approximately 1,300 lawsuits pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside of the U.S. Most of the actions were brought by contractors who worked at sites between the 1950s and the 1990s. A small number of cases involve similar allegations by DuPont employees or household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products.

At June 30, 2019 and December 31, 2018, Chemours had an accrual of \$37 related to these matters.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

***Benzene***

In the separation, DuPont assigned its benzene docket to Chemours. At June 30, 2019 and December 31, 2018, there were 19 cases pending against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products such as paints, thinners, and reducers.

Management believes that a loss is reasonably possible as to the docket as a whole; however, given that the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure, and other factors, a range of such losses cannot be reasonably estimated at this time.

***PFOA***

Prior to the fourth quarter of 2014, the performance chemicals segment of DuPont made “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) at its Fayetteville, North Carolina plant and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites, including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and, Shimizu, Japan. These sites are now owned and/or operated by Chemours.

Chemours maintained accruals of \$22 related to the PFOA matters discussed below at June 30, 2019 and December 31, 2018. These accruals relate to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (“EPA”) and voluntary commitments to the New Jersey Department of Environmental Protection (“NJ DEP”). These obligations and voluntary commitments include surveying, sampling, and testing drinking water in and around certain Company sites offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the state or the national health advisory. The Company will continue to work with the EPA regarding the extent of work that may be required with respect to these matters.

***Leach Settlement***

In 2004, DuPont settled a class action captioned *Leach v. DuPont*, filed in West Virginia state court, alleging that approximately 80,000 residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. Among the settlement terms, DuPont funded a series of health studies by an independent science panel of experts (“C8 Science Panel”) to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and disease.

The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and diagnosed high cholesterol. Under the terms of the settlement, DuPont is obligated to fund up to \$235 for a medical monitoring program for eligible class members and pay the administrative costs associated with the program, including class counsel fees. The court-appointed Director of Medical Monitoring implemented the program and testing is ongoing with associated payments to service providers disbursed from an escrow account which the Company replenishes pursuant to the settlement agreement. As of June 30, 2019, approximately \$1.7 has been disbursed from escrow related to medical monitoring. While it is reasonably possible that the Company will incur additional costs related to the medical monitoring program, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the Leach settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts and private well users. At separation, this obligation was assigned to Chemours and is included in the \$22 accrued for these matters at June 30, 2019 and December 31, 2018.

***PFOA Leach Class Personal Injury***

Further, under the Leach settlement, class members may pursue personal injury claims against DuPont only for those diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were subsequently filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation (“MDL”) in Ohio federal court. These were resolved in March 2017 when DuPont entered into an agreement settling all MDL cases and claims, including all filed and unfiled personal injury cases and claims that were part of the plaintiffs’ counsel’s claims inventory, as well as cases tried to a jury verdict (“MDL Settlement”) for \$670.7 in cash, with half paid by Chemours, and half paid by DuPont.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

Concurrently with the MDL Settlement, DuPont and Chemours agreed to a limited sharing of potential future PFOA costs (indemnifiable losses, as defined in the separation agreement between DuPont and Chemours) for a period of five years. During that five-year period, Chemours will annually pay future PFOA costs up to \$25 and, if such amount is exceeded, DuPont will pay any excess amount up to the next \$25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms of the separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours' indemnification obligations under the separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the separation agreement for PFOA costs on the basis of ostensible defenses generally applicable to the indemnification provisions under the separation agreement, including defenses relating to punitive damages, fines or penalties, or attorneys' fees, and waives any such defenses with respect to PFOA costs. Chemours has, however, retained other defenses, including as to whether any particular PFOA claim is within the scope of the indemnification provisions of the separation agreement.

While all MDL lawsuits were dismissed or resolved through the MDL Settlement, the MDL Settlement did not resolve PFOA personal injury claims of plaintiffs who did not have cases or claims in the MDL or personal injury claims based on diseases first diagnosed after February 11, 2017. Since the resolution of the MDL, approximately 57 personal injury cases have been filed and are pending in West Virginia or Ohio courts alleging status as a Leach class member. These cases are consolidated before the MDL court with trials for individual plaintiffs scheduled in October 2019 and January 2020, and for six plaintiffs in June 2020.

#### *State of Ohio*

In February 2018, the State of Ohio initiated litigation against DuPont regarding historical PFOA emissions from the Washington Works site. Chemours is an additional named defendant. Ohio alleges damage to natural resources and seeks damages including remediation and other costs and punitive damages.

#### **PFAS**

DuPont and Chemours have been named in other litigations brought by individuals, water districts, businesses, and a putative national medical monitoring putative class action alleging exposure to and/or contamination from perfluorinated and polyfluorinated compounds ("PFAS"), including PFOA.

#### *Aqueous Film Forming Foam Matters*

DuPont and Chemours have been named in 15 matters, brought by plaintiffs other than states, involving aqueous film forming foam ("AFFF"), which is used to extinguish hydrocarbon-based (i.e., Class B) fires and subject to U.S. military specifications. Some matters have been transferred to a multidistrict litigation ("AFFF MDL") in South Carolina federal court.

In February 2019, two commercial dairy farms near Cannon Air Force Base in New Mexico filed lawsuits in federal court in New Mexico against DuPont and Chemours, as well as against several manufacturers of AFFF. These cases allege that decades of use of AFFF for firefighting practice at the nearby Air Force base contaminated the groundwater, the aquifer, and the property with PFAS, including PFOA and "PFOS" (perfluorooctane sulfonic acid) and threatens their milk and crop production. These cases allege that DuPont and Chemours manufactured AFFF and its non-defined "constituents." Plaintiffs seek to recover damages for investigating, monitoring, remediating, treating, and otherwise responding to the contamination, and punitive damages.

Also in February 2019, the City of Dayton, Ohio ("City") filed an amended complaint to add DuPont and Chemours as defendants to a lawsuit filed in Ohio federal court against numerous AFFF manufacturers. The City alleges that decades of AFFF use in firefighting practice at Wright-Patterson Air Force Base in Ohio and at the City's own firefighting practice center contaminated the drinking water supply. The City alleges that DuPont and Chemours manufactured AFFF and its non-defined "constituents." The City seeks to recover damages for investigating, monitoring, remediating, treating, and otherwise responding to the PFAS contamination and punitive damages. The case was transferred to the AFFF MDL.

In April 2019, the Atlantic City Municipal Utilities Authority filed a complaint in New Jersey federal court against AFFF manufacturers, the Federal Aviation Administration ("FAA"), DuPont, and Chemours regarding use of AFFF at William J. Hughes Technical Center in New Jersey, an FAA-owned site. Plaintiffs allege that DuPont manufactured, marketed, sold, or otherwise promoted the use of AFFF and that Chemours is responsible for sharing DuPont liabilities. The plaintiff seeks to recover damages including clean-up costs, compensatory, and punitive damages regarding contamination of its drinking water wells.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

In May 2019, two individuals formerly employed as firefighters at the Naval Air Station Joint Reserve Base in Belle Chase, Louisiana filed personal injury cases against numerous defendants who allegedly designed, marketed, developed, manufactured, distributed, trained users, produced instructional materials, sold, or otherwise handled or used AFFF. These lawsuits were filed directly into the AFFF MDL.

In May 2019, two putative class actions were filed in federal courts in Michigan and New Hampshire seeking class status for individuals who have lived or worked on the former Pease Air Force Base and Wurtsmith Air Force Base who consumed public water. The lawsuits are filed against several defendants alleged to have designed, manufactured, and sold AFFF and/or PFAS constituents of AFFF. Plaintiffs seek damages including medical monitoring.

Valero Refining (“Valero”) filed four state court lawsuits in June 2019 regarding its Tennessee, Texas, Oklahoma, and California facilities. These lawsuits allege that several defendants that designed, manufactured, marketed, and/or sold AFFF or PFAS incorporated into AFFF have caused Valero to incur damages and costs including remediation, AFFF disposal, and replacement. Valero also alleges fraudulent transfer in DuPont’s spin-off that created Chemours.

In June 2019, the County of Dutchess, New York filed a putative class action on behalf of other state water suppliers having any detectable amounts of PFOA and/or PFOS in their water supply. The matter was filed directly into the AFFF MDL against numerous defendants who allegedly designed, manufactured, marketed, and sold AFFF. Plaintiffs seek damages including treatment, extending and/or modifying systems, and testing.

In June and July 2019, the City of Sioux Falls and Sioux Falls Regional Airport filed complaints directly into the AFFF MDL against numerous defendants who allegedly manufactured, distributed, and/or sold AFFF seeking damages for contamination to land, water, and structures. The plaintiff also alleges fraudulent transfer in DuPont’s spin-off that created Chemours and seeks damages for costs including investigation, remediation, disposal monitoring, and punitive damages.

#### *State Natural Resource Damages Matters*

In addition to the State of New Jersey actions (as detailed below) and the State of Ohio action (as detailed above), the states of Vermont and New Hampshire have each filed two lawsuits against defendants, including DuPont and Chemours, relating to the alleged contamination of state natural resources with PFAS compounds. These lawsuits seek damages including costs to investigate, clean up, restore, treat, monitor, or otherwise respond to contamination to natural resources.

Each state has filed one lawsuit against 3M Company (“3M”), DuPont, and Chemours generally alleging widespread contamination of the state’s natural resources with PFAS and damaging the value and use of natural resources as well as injuring citizens of the states. The second lawsuit filed by each state is against alleged manufacturers of AFFF, including DuPont and Chemours. This second action generally demands that the defendants pay for all costs to respond to contamination of the state’s property and resources and other damages. All these lawsuits include counts for fraudulent transfer, either under state law or uniform acts, relating to DuPont’s spin-off that created Chemours.

#### *Other PFAS Matters*

DuPont has also been named in approximately 49 lawsuits pending in New York courts, which are not part of the Leach class, brought by individual plaintiffs alleging negligence and other claims in the release of PFAS, including PFOA, into drinking water, and seeking medical monitoring, compensatory, and punitive damages against current and former owners and suppliers of a manufacturing facility in Hoosick Falls, New York. The Company has been included as a named defendant in seven of these lawsuits. Two other lawsuits in New York have been filed by a business seeking to recover its losses and by nearby property owners and residents in a putative class action seeking medical monitoring, compensatory and punitive damages, and injunctive relief.

In May 2017, the Water Works and Sewer Board of the Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia and suppliers and former suppliers, including DuPont, in Alabama state court. The complaint alleges negligence, nuisance, and trespass in the release of PFAS, including PFOA, into a river leading to the town’s water source, and seeks compensatory and punitive damages.

In February 2018, the New Jersey-American Water Company, Inc. (“NJAW”) filed suit against DuPont and Chemours in New Jersey federal court alleging that discharges in violation of the New Jersey Spill Compensation and Control Act (“Spill Act”), were made into groundwater utilized in the NJAW Penns Grove water system. NJAW alleges that damages include costs associated with remediating, operating, and maintaining its system, and attorney fees.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

In October 2018, a putative class action was filed in Ohio federal court against 3M, DuPont, Chemours, and other defendants seeking class action status for U.S. residents having a detectable level of PFAS in their blood serum. The complaint seeks declaratory and injunctive relief, including the establishment of a “PFAS Science Panel.”

In December 2018, the owners of a dairy farm filed a lawsuit in Maine state court against numerous defendants including DuPont and Chemours alleging that their dairy farm was contaminated by PFAS, including PFOS and PFOA present in treated municipal sewer sludge used in agricultural spreading applications on their farm. The complaint asserts negligence, trespass, and other tort and state statutory claims and seeks damages.

In January 2019, the Town of East Hampton, New York (“Town”) filed a lawsuit against DuPont, Chemours, and numerous other defendants in New York state court alleging that it has and will incur costs for assessment, remediation, and response to address PFAS contamination, including PFOA and PFOS in drinking water and the environment. As to DuPont and Chemours, the Town alleges that PFOA and/or PFOS washed from clothing or cleaning supplies to cesspools and then subsurface water. In addition to cost recovery, the Town seeks natural resource damages, compensatory and punitive damages, and injunctive relief. Other defendants, identified as manufacturers of AFFF, transferred the case to the AFFF MDL.

In February 2019, the Ridgewood City Water Department (“Ridgewood Water”), a public water supplier in Bergen County, New Jersey filed a lawsuit in New Jersey state court against DuPont, Chemours, and numerous other defendants. As to DuPont and Chemours, Ridgewood Water alleges that “PTFE” (polytetrafluoroethylene fluoropolymers) is one of the sources of alleged PFAS contamination, including PFOA and PFOS. Ridgewood Water seeks declaratory relief requiring defendants to pay for assessment, remediation, and response costs, as well as compensatory and punitive damages.

In May 2019, a putative class action was filed in Delaware state court against two electroplating companies alleging that they are responsible for PFAS contamination, including PFOA and PFOS, in drinking water and the environment in the nearby community. The suit also names 3M, DuPont and Chemours, asserting they sold PFAS containing materials to the electroplating companies. The putative class of residents alleges negligence, nuisance, trespass and other claims and seeks medical monitoring, personal injury and property damages, and punitive damages.

***New Jersey Department of Environmental Protection Directives and Litigation***

In March 2019, the NJ DEP issued two Directives and filed four lawsuits against Chemours and other defendants. The Directives are: (i) a state-wide PFAS Directive issued to DuPont, DowDuPont, DuPont Specialty Products USA (“DuPont SP USA”), Solvay S.A., 3M and Chemours seeking a meeting to discuss future costs for PFAS related costs incurred by the NJ DEP and establishing a funding source for such costs by the Directive recipients, and information relating to historic and current use of certain PFAS compounds; and, (ii) a Pompton Lakes Natural Resources Damages (“NRD”) Directive to DuPont and Chemours demanding \$0.1 to cover the cost of preparation of a natural resource damage assessment plan and access to related documents.

The lawsuits filed in New Jersey state courts by the NJ DEP are: (i) in Salem County, against DuPont, 3M, and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, the Water Pollution Control Act (“WPCA”), the Industrial Site Recovery Act (“ISRA”), and common law regarding past and present operations at Chambers Works, a site assigned to Chemours at separation; (ii) in Middlesex County, against DuPont, DuPont SP USA, 3M, and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, ISRA, WPCA, and common law regarding past and present operations at Parlin, a DuPont owned site; (iii) in Gloucester County, against DuPont and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, WPCA, and common law regarding past operations at Repauno, a non-operating remediation site assigned to Chemours at separation which has been sold; and (iv) in Passaic County, against DuPont and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, WPCA, and common law regarding past operations at Pompton Lakes, a non-operating remediation site assigned to Chemours at separation. The alleged pollutants listed in the Salem County and Middlesex County matters above include PFAS. The lawsuits were amended to add counts of fraudulent transfer in connection with DuPont’s spin-off that created Chemours.

DuPont requested that Chemours defend and indemnify it in these matters. Chemours has accepted the defense while reserving rights and declining DuPont’s demand as to matters under ISRA, fraudulent transfer or involving other DuPont entities.

***PFOA and PFAS Summary***

Management believes that it is reasonably possible that the Company could incur losses related to PFOA and/or PFAS matters in excess of amounts accrued, but any such losses are not estimable at this time due to various reasons, including, among others, that such matters are in their early stages and have significant factual issues to be resolved.

***U.S. Smelter and Lead Refinery, Inc.***

There are six lawsuits, including one putative class action, pending against DuPont by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Several of the lawsuits allege that Chemours is now responsible for DuPont environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution, and damages under the Comprehensive Environmental Response Compensation and Liability Act (“CERCLA,” often referred to as “Superfund”). At separation, DuPont assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in their early stages and have significant factual issues to be resolved.

***GenX and Other Perfluorinated and Polyfluorinated Compounds***

At its Fayetteville, North Carolina facility, the Company continues to capture and separately dispose of process waste water containing the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid,” sometimes referred to as “GenX” or “C3 Dimer Acid”) and other perfluorinated and polyfluorinated compounds. The Company believes that discharges to the Cape Fear River, site surface water, groundwater, and air emissions have not impacted the safety of drinking water in North Carolina and is cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities. Government inquiries include an investigation regarding PFAS chemicals (including GenX) initiated in July 2019 by the U.S. House of Representatives Committee on Oversight and Reform, Subcommittee on the Environment and an ongoing investigation into releases from the Fayetteville site being conducted by the U.S. Attorney’s Office for the Eastern District of North Carolina and the Environment and Natural Resources Division of the U.S. Department of Justice.

In September 2017, the North Carolina Department of Environmental Quality (“NC DEQ”) issued a 60-day notice of intent to suspend the permit for the Fayetteville facility and the State of North Carolina filed an action in North Carolina state court regarding the discharges seeking a temporary restraining order and preliminary injunction, as well as other relief, including abatement and site correction. A partial Consent Order was entered partially resolving the State’s action in return for the Company’s agreement to continue and supplement the voluntary waste water disposal measures it had previously commenced and to provide certain information. In November 2017, the NC DEQ informed the Company that it was suspending the process waste water discharge permit for the Fayetteville facility. The Company thereafter commenced the capture and separate disposal of all process waste water from the Fayetteville facility related to the Company’s own operations. In addition, in June 2018, the North Carolina Legislature enacted legislation (i) granting the governor the authority, in certain circumstances, to require a facility with unauthorized PFAS discharges to cease operations, and (ii) granting the governor the authority, in certain circumstances, to direct the NC DEQ secretary to order a PFAS discharger to establish permanent replacement water supplies for parties whose water was contaminated by the discharge.

On July 13, 2018, Cape Fear River Watch (“CFRW”), a non-profit organization, sued the NC DEQ in North Carolina state court, seeking to require the NC DEQ to take additional actions as to the Fayetteville facility. On August 29, 2018, CFRW sued the Company in North Carolina federal court for alleged violations of the Clean Water Act (“CWA”) and the Toxic Substances Control Act (“TSCA”), seeking declaratory and injunctive relief and penalties.

On February 25, 2019, the North Carolina Superior Court for Bladen County approved a Consent Order between NC DEQ and the Company resolving the State’s and CFRW’s lawsuits and other matters (including issues regarding the legislation referenced above and Notices of Violation (“NOVs”) issued by the State) and litigation brought by CFRW. Under its terms, Chemours paid \$13 in March 2019 to cover a civil penalty and investigative costs and continues to take additional actions to address site surface water, groundwater, and air emissions, including installing technology to abate future emissions by specified dates and meeting specified emissions reductions (with stipulated penalties for failures to do so). In connection with the approved Consent Order, the Company accrued an additional \$7 during the second quarter of 2019 and had total accrued liabilities of \$87 for this matter at June 30, 2019, of which, \$56 is treated as accrued litigation costs. The Company’s estimated liability is based on management’s assessment of the current facts and circumstances for this matter, which are subject to various assumptions that include, but are not limited to, the number of affected properties, the type of water treatment system required, the cost of proposed water treatment systems and any related operation, maintenance, and monitoring (“OM&M”) requirements, assessed fines and penalties, and other charges contemplated by the Consent Order.

In February 2019, the Company received an NOV from the EPA alleging certain TSCA violations at its Fayetteville site. Matters raised in the NOV could have the potential to affect operations at the Fayetteville site. The Company responded to the EPA in March 2019 asserting that the Company has not violated environmental laws. At this time, management does not believe that a loss is probable related to the matters in this NOV.

It is also possible that issues relating to site discharges could result in further litigation or regulatory demands with regard to the Fayetteville facility, including potential permit modifications. If such issues arise, if the Consent Order is modified, or as implementation of the obligations under the Consent Order proceed, an additional loss is reasonably possible but not estimable at this time.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The Company has responded to grand jury subpoenas, produced witnesses before a grand jury and for interviews with government investigators and attorneys, and met with the U.S. Attorney's Office for the Eastern District of North Carolina and the Environment and Natural Resources Division of the U.S. Department of Justice regarding their investigation into a potential violation of the CWA. Although the Company is not able at this point to predict the outcome of that investigation, it is reasonably possible that it could result in a criminal or civil proceeding, the imposition of fines and penalties, and/or other remedies.

Civil actions have been filed against DuPont and Chemours in North Carolina federal court relating to discharges from the Fayetteville site. These actions include a consolidated action brought by public water suppliers seeking damages and injunctive relief, a consolidated purported class action seeking medical monitoring, and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River, and an action by private well owners seeking compensatory and punitive damages. It is possible that additional litigation may be filed against the Company and/or DuPont concerning the discharges. Ruling on the Company's motions in April 2019, the court dismissed the medical monitoring, injunctive demand, and many other alleged causes of actions in these lawsuits.

It is not possible at this point to predict the timing, course, or outcome of all governmental and regulatory inquiries and notices and litigation, and it is possible that these matters could materially affect the Company's financial results and operations. In addition, local communities, organizations, and federal and state regulatory agencies have raised questions concerning HFPO Dimer Acid and other perfluorinated and polyfluorinated compounds at certain other manufacturing sites operated by the Company, and it is possible that similar developments to those described above and centering on the Fayetteville site could arise in other locations.

### ***Mining Solutions Facility Construction Stoppage***

In March 2018, a civil association in Mexico filed a complaint against the government authorities involved in the permitting process of the Company's new Mining Solutions facility under construction in Gomez Palacio, Durango, Mexico. The claimant sought and obtained a suspension from the district judge to stop the Company's construction work while the claim is studied and reviewed. Chemours, as the third-party affected, has filed an appeal. The Company has declared force majeure with its vendors while plant construction is idled. Chemours' project permits fully comply with the laws and regulations at the federal, state, and municipal levels, and the Company is working with local and federal authorities, along with community leaders, to address the complaint.

Management determined that these delays represented a trigger event, which required approximately \$140 long-lived assets under construction at the facility and approximately \$50 of the Company's Mining Solutions reporting unit's goodwill to be tested for impairment at June 30, 2019. No impairments were noted as a result of these tests. If the Company is unable to resume construction on the facility, a significant portion of the associated long-lived assets could be impaired, and the Company may owe additional payments to certain vendors as a result of terminating contractual agreements.

### ***Environmental***

Chemours, due to the terms of its separation-related agreements with DuPont, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Much of this liability results from CERCLA, the Resource Conservation and Recovery Act, and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation, and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based on existing remediation laws and technologies. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technological, regulatory, and legal information becomes available. Environmental liabilities and expenditures include claims for matters that are liabilities of DuPont and its subsidiaries, which Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the Company's separation from DuPont. These accrued liabilities are undiscounted and do not include claims against third-parties. Costs related to environmental remediation are charged to expense in the period incurred.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The following table sets forth the components of the Company's environmental remediation liabilities at June 30, 2019 and December 31, 2018, and illustrates the five sites that are deemed the most significant by management.

	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Chambers Works, Deepwater, New Jersey	\$ 20	\$ 18
East Chicago, Indiana	20	21
Fayetteville Works, Fayetteville, North Carolina (1)	31	10
Pompton Lakes, New Jersey	43	45
USS Lead, East Chicago, Indiana	14	15
All other sites	116	117
<b>Total accrued environmental remediation</b>	<b>\$ 244</b>	<b>\$ 226</b>

(1) Total accruals related to this matter amounted to \$87 and \$75 at June 30, 2019 and December 31, 2018, respectively. These amounts included \$56 and \$65, which are reflected as a component of the Company's accrued litigation at June 30, 2019 and December 31, 2018, respectively.

The following table sets forth the current and long-term components of the Company's environmental remediation liabilities and their balance sheet locations at June 30, 2019 and December 31, 2018.

	<b>Balance Sheet Location</b>	<b>June 30, 2019</b>	<b>December 31, 2018</b>
<b>Environmental remediation:</b>			
Current environmental remediation	Other accrued liabilities (Note 16)	\$ 78	\$ 74
Long-term environmental remediation	Other liabilities (Note 18)	166	152
<b>Total accrued environmental remediation</b>		<b>\$ 244</b>	<b>\$ 226</b>

At June 30, 2019 and December 31, 2018, the consolidated balance sheets included liabilities relating to these matters of \$244 and \$226, respectively, which, in management's opinion, are appropriate based on existing facts and circumstances. The time-frame for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify DuPont pursuant to the separation-related agreements, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs. While the Company currently estimates that, in view of that uncertainty, the potential liability may range up to approximately \$480 above the amount accrued at June 30, 2019, the amounts could be substantially higher than this range under adverse changes in circumstances.

Chemours incurred environmental remediation expenses of \$17 and \$32 for the three and six months ended June 30, 2019, respectively, and \$13 and \$24 for the three and six months ended June 30, 2018, respectively.

**Note 20. Equity**

On August 1, 2018, the Company's board of directors approved a share repurchase program authorizing the purchase of shares of Chemours' issued and outstanding common stock in an aggregate amount not to exceed \$750, plus any associated fees or costs in connection with the Company's share repurchase activity ("2018 Share Repurchase Program"). On February 13, 2019, the Company's board of directors increased the authorization amount of the 2018 Share Repurchase Program from \$750 to \$1,000. Under the 2018 Share Repurchase Program, shares of Chemours' common stock can be purchased on the open market from time to time, subject to management's discretion, as well as general business and market conditions. The Company's 2018 Share Repurchase Program became effective on August 1, 2018 and will continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

Under the 2018 Share Repurchase Program, the Company purchased an additional 1,617,140 shares of Chemours' issued and outstanding common stock during the second quarter of 2019, which amounted to \$61 at an average share price of \$37.93 per share. As of June 30, 2019, the Company has purchased a cumulative 15,245,999 shares of Chemours' issued and outstanding common stock under the 2018 Share Repurchase Program, which amounted to \$572 at an average share price of \$37.52 per share. The aggregate amount of Chemours' common stock that remained available for purchase under the 2018 Share Repurchase Program at June 30, 2019 was \$428.

**Note 21. Stock-based Compensation**

The Company's total stock-based compensation expense was \$6 and \$14 for the three and six months ended June 30, 2019, respectively, and \$6 and \$15 for the three and six months ended June 30, 2018, respectively.

**Stock Options**

During the six months ended June 30, 2019, Chemours granted approximately 840,000 non-qualified stock options to certain of its employees, which will vest over a three-year period and expire 10 years from the date of grant. The fair value of the Company's stock options are based on the Black-Scholes valuation model.

The following table sets forth the assumptions used to determine the fair value of the Company's stock option awards that were granted during the six months ended June 30, 2019.

	<b>Six Months Ended June 30, 2019</b>
Risk-free interest rate	2.53%
Expected term (years)	6.05
Volatility	48.05%
Dividend yield	2.81%
<b>Fair value per stock option</b>	<b>\$ 13.66</b>

The Company recorded \$2 and \$6 in stock-based compensation expense specific to its stock options for the three and six months ended June 30, 2019, respectively, and \$1 and \$6 in stock-based compensation expense specific to its stock options for the three and six months ended June 30, 2018, respectively. At June 30, 2019, approximately 6,220,000 stock options remained outstanding.

**Restricted Stock Units**

During the six months ended June 30, 2019, Chemours granted approximately 180,000 restricted stock units ("RSUs") to certain of its employees, which will vest over a three-year period and, upon vesting, convert one-for-one to Chemours' common stock. The fair value of the RSUs is based on the market price of the underlying common stock at the grant date.

The Company recorded \$2 and \$4 in stock-based compensation expense specific to its RSUs for the three and six months ended June 30, 2019, respectively, and \$3 and \$5 in stock-based compensation expense specific to its RSUs for the three and six months ended June 30, 2018, respectively. At June 30, 2019, approximately 230,000 RSUs remained non-vested.

**Performance Share Units**

During the six months ended June 30, 2019, Chemours granted approximately 240,000 performance share units ("PSUs") to key senior management employees, which, upon vesting, convert one-for-one to Chemours' common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 250% of the target amount depending on the Company's performance against stated performance goals.

During the six months ended June 30, 2019, approximately 1,520,000 PSUs granted in 2016 to the Company's key senior management employees vested, based on the attainment of certain performance and market-based conditions. Of the 1,520,000 PSUs that vested during the six months ended June 30, 2019, approximately 680,000 non-issued shares were cancelled to cover the employee portion of income taxes related to this award.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company's stock at the grant date, regardless of whether the market-based conditions are satisfied.

The Company recorded \$2 and \$4 in stock-based compensation expense specific to its PSUs for the three and six months ended June 30, 2019, respectively, and \$2 and \$4 in stock-based compensation expense specific to its PSUs for the three and six months ended June 30, 2018. At June 30, 2019, approximately 540,000 PSUs at 100% of the target amount remained non-vested.

### ***Employee Stock Purchase Plan***

On January 26, 2017, the Company's board of directors approved The Chemours Company Employee Stock Purchase Plan ("ESPP"), which was approved by Chemours' stockholders on April 26, 2017. Under the ESPP, a total of 7,000,000 shares of Chemours' common stock are reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with two purchase periods in March and September within those offering periods. The initial offering period under the ESPP began on October 2, 2017. Participating employees are eligible to purchase the Company's common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period. During the six months ended June 30, 2019 and 2018, the Company executed open market transactions to purchase the Company's common stock on behalf of its ESPP participants, which amounted to approximately 25,000 shares at \$1 and 12,000 shares at less than \$1, respectively. Additionally, in the second quarter of 2018, the Company issued approximately 12,000 shares out of its treasury stock to ESPP participants, which amounted to less than \$1.

## **Note 22. Financial Instruments**

### ***Derivative Instruments***

#### ***Objectives and Strategies for Holding Derivative Instruments***

In the ordinary course of business, Chemours enters into contractual arrangements (i.e., derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management, which currently includes three distinct risk management strategies: (i) foreign currency forward contracts, which are used to minimize the volatility in the Company's earnings related to foreign exchange gains and losses resulting from remeasuring its monetary assets and liabilities that are denominated in non-functional currencies; (ii) foreign currency forward contracts, which are also used to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of the Company's international subsidiaries that use the euro as their functional currency; and, (iii) euro-denominated debt, which is used to reduce the volatility in stockholders' equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar for certain of its international subsidiaries that use the euro as their functional currency. The Company's derivative program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program operates within Chemours' financial risk management policies and guidelines, and the Company does not enter into derivative financial instruments for trading or speculative purposes.

#### ***Net Monetary Assets and Liabilities Hedge – Foreign Currency Forward Contracts***

At June 30, 2019, the Company had 14 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of \$425, and an average maturity of one month. At December 31, 2018, the Company had 20 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of \$503, and an average maturity of one month. Chemours recognized a net gain of \$1 and a net loss of \$1 for the three and six months ended June 30, 2019, respectively, and net losses of \$8 and \$5 for the three and six months ended June 30, 2018, respectively, on its foreign currency forward contracts in other income, net.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
(Dollars in millions, except per share amounts)

*Cash Flow Hedge – Foreign Currency Forward Contracts*

At June 30, 2019, the Company had 123 foreign currency contracts outstanding under Chemours' cash flow hedge program with an aggregate notional U.S. dollar equivalent of \$137, and an average maturity of four months. At December 31, 2018, the Company had 75 foreign currency contracts outstanding under Chemours' cash flow hedge program with an aggregate notional U.S. dollar equivalent of \$143, and an average maturity of four months. The Company recognized a pre-tax gain of \$2 for the six months ended June 30, 2019, and pre-tax gains of \$7 for the three and six months ended June 30, 2018 on its cash flow hedge within accumulated other comprehensive loss. For the three and six months ended June 30, 2019, \$3 and \$6 of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss. No amounts were reclassified to the cost of goods sold from accumulated other comprehensive loss during the three and six months ended June 30, 2018.

The Company expects to reclassify an approximate \$3 of net gain from accumulated other comprehensive loss to the cost of goods sold over the next 12 months, based on current foreign currency exchange rates.

*Net Investment Hedge – Foreign Currency Borrowings*

The Company recognized a pre-tax loss of \$7 and a pre-tax gain of \$3 for the three and six months ended June 30, 2019, respectively, and pre-tax gains of \$48 and \$13 for the three and six months ended June 30, 2018, respectively, on its net investment hedges within accumulated other comprehensive loss. No amounts were reclassified from accumulated other comprehensive loss for the Company's net investment hedges during the three and six months ended June 30, 2019 and 2018.

**Fair Value of Derivative Instruments**

The following table sets forth the fair value of the Company's derivative assets and liabilities at June 30, 2019 and December 31, 2018.

	<b>Balance Sheet Location</b>	<b>Fair Value Using Level 2 Inputs</b>	
		<b>June 30, 2019</b>	<b>December 31, 2018</b>
<b>Asset derivatives:</b>			
Foreign currency forward contracts not designated as a hedging instrument	Accounts and notes receivable, net (Note 9)	\$ —	\$ 1
Foreign currency forward contracts designated as a cash flow hedge	Accounts and notes receivable, net (Note 9)	1	3
<b>Total asset derivatives</b>		<b>\$ 1</b>	<b>\$ 4</b>
<b>Liability derivatives:</b>			
Foreign currency forward contracts not designated as a hedging instrument	Other accrued liabilities (Note 16)	\$ 1	\$ 1
<b>Total liability derivatives</b>		<b>\$ 1</b>	<b>\$ 1</b>

The Company's foreign currency forward contracts are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on the quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data, and are subjected to tolerance and/or quality checks.



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Summary of Derivative Instruments**

The following table sets forth the pre-tax changes in fair value of the Company's derivative assets and liabilities for the three and six months ended June 30, 2019 and 2018.

	<b>Gain (Loss) Recognized In</b>		
	<b>Cost of Goods Sold</b>	<b>Other Income, Net</b>	<b>Other Comprehensive Income (Loss)</b>
<b>Three months ended June 30,</b>			
<b>2019</b>			
Foreign currency forward contracts not designated as a hedging instrument	\$ —	\$ 1	\$ —
Foreign currency forward contracts designated as a cash flow hedge	3	—	—
Euro-denominated debt designated as a net investment hedge	—	—	(7)
<b>2018</b>			
Foreign currency forward contracts not designated as a hedging instrument	\$ —	\$ (8)	\$ —
Foreign currency forward contracts designated as a cash flow hedge	—	—	7
Euro-denominated debt designated as a net investment hedge	—	—	48

	<b>Gain (Loss) Recognized In</b>		
	<b>Cost of Goods Sold</b>	<b>Other Income, Net</b>	<b>Other Comprehensive Income (Loss)</b>
<b>Six months ended June 30,</b>			
<b>2019</b>			
Foreign currency forward contracts not designated as a hedging instrument	\$ —	\$ (1)	\$ —
Foreign currency forward contracts designated as a cash flow hedge	6	—	2
Euro-denominated debt designated as a net investment hedge	—	—	3
<b>2018</b>			
Foreign currency forward contracts not designated as a hedging instrument	\$ —	\$ (5)	\$ —
Foreign currency forward contracts designated as a cash flow hedge	—	—	7
Euro-denominated debt designated as a net investment hedge	—	—	13

**Note 23. Long-term Employee Benefits**

Chemours sponsors defined benefit pension plans for certain of its employees in various jurisdictions outside of the U.S. The Company's net periodic pension (cost) income is based on estimated values and the use of assumptions about the discount rate, expected return on plan assets, and the rate of future compensation increases received by its employees.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The following table sets forth the Company's net periodic pension (cost) income and amounts recognized in other comprehensive income for the three and six months ended June 30, 2019 and 2018.

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Service cost	\$ (3)	\$ (4)	\$ (6)	\$ (7)
Interest cost	(4)	(4)	(9)	(9)
Expected return on plan assets	13	14	26	29
Amortization of actuarial loss	(7)	(4)	(12)	(7)
Amortization of prior service cost	1	1	1	1
Settlement loss	—	—	(1)	—
<b>Total net periodic pension (cost) income</b>	<b>\$ —</b>	<b>\$ 3</b>	<b>\$ (1)</b>	<b>\$ 7</b>
Net loss	\$ (3)	\$ —	\$ (3)	\$ —
Prior service benefit	5	—	5	—
Amortization of prior service cost	(1)	(1)	(1)	(1)
Amortization of actuarial loss	7	\$ 4	\$ 12	\$ 7
Settlement loss	—	—	1	—
Effect of foreign exchange rates	(2)	13	1	5
Benefit recognized in other comprehensive income (loss)	6	16	15	11
<b>Total changes in plan assets and benefit obligations recognized in other comprehensive income (loss)</b>	<b>\$ 6</b>	<b>\$ 19</b>	<b>\$ 14</b>	<b>\$ 18</b>

The Company made cash contributions of \$6 and \$13 to its defined benefit pension plans during the three and six months ended June 30, 2019, respectively, and \$4 and \$8 for the three and six months ended June 30, 2018, respectively, and expects to make additional cash contributions of \$8 to its defined benefit pension plans during the remainder of 2019.

**Note 24. Segment Information**

Chemours' reportable segments are Fluoroproducts, Chemical Solutions, and Titanium Technologies. Corporate costs and certain legal and environmental expenses, stock-based compensation expenses, and foreign exchange gains and losses arising from the remeasurement of balances in currencies other than the functional currency of the Company's legal entities are reflected in Corporate and Other.

Segment net sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on research and development facilities and the amortization of other intangible assets, excluding any write-downs of assets.

Adjusted earnings before interest, taxes, depreciation, and amortization ("Adjusted EBITDA") is the primary measure of segment profitability used by the Company's Chief Operating Decision Maker and is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of assets and businesses; and,
- other items not considered indicative of the Company's ongoing operational performance and expected to occur infrequently.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

The following table sets forth certain summary financial information for the Company's reportable segments for the three and six months ended June 30, 2019 and 2018.

<b>Three Months Ended June 30,</b>	<b>Fluoroproducts</b>		<b>Chemical Solutions</b>		<b>Titanium Technologies</b>		<b>Segment Total</b>
<b>2019</b>							
Net sales to external customers	\$	711	\$	130	\$	567	\$ 1,408
Adjusted EBITDA		180		16		127	323
Depreciation and amortization		34		5		30	69
<b>2018</b>							
Net sales to external customers	\$	801	\$	153	\$	862	\$ 1,816
Adjusted EBITDA		230		16		295	541
Depreciation and amortization		30		5		30	65
<b>Six Months Ended June 30,</b>	<b>Fluoroproducts</b>		<b>Chemical Solutions</b>		<b>Titanium Technologies</b>		<b>Segment Total</b>
<b>2019</b>							
Net sales to external customers	\$	1,398	\$	264	\$	1,122	\$ 2,784
Adjusted EBITDA		339		31		253	623
Depreciation and amortization		66		13		60	139
<b>2018</b>							
Net sales to external customers	\$	1,532	\$	297	\$	1,717	\$ 3,546
Adjusted EBITDA		437		26		589	1,052
Depreciation and amortization		59		9		60	128

Corporate and Other depreciation and amortization expense amounted to \$9 and \$18 for the three and six months ended June 30, 2019, respectively, and \$7 and \$14 for the three and six months ended June 30, 2018, respectively.

The following table sets forth a reconciliation of segment Adjusted EBITDA to the Company's consolidated net income before income taxes for the three and six months ended June 30, 2019 and 2018.

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<b>Segment Adjusted EBITDA</b>	\$ 323	\$ 541	\$ 623	\$ 1,052
Corporate and Other	(40)	(44)	(78)	(87)
Interest expense, net	(52)	(48)	(103)	(100)
Depreciation and amortization	(78)	(72)	(154)	(142)
Non-operating pension and other post-retirement employee benefit income	3	7	6	14
Exchange (losses) gains, net	(9)	2	(3)	2
Restructuring, asset-related, and other charges (1)	(7)	(10)	(15)	(20)
Loss on extinguishment of debt	—	(38)	—	(38)
Gain on sales of assets and businesses (2)	2	3	2	45
Transaction costs	(1)	(9)	(1)	(9)
Legal charges (3)	(8)	(9)	(38)	(13)
<b>Income before income taxes</b>	<b>\$ 133</b>	<b>\$ 323</b>	<b>\$ 239</b>	<b>\$ 704</b>

- (1) Includes restructuring, asset-related, and other charges, which are discussed in further detail in "Note 5 – Restructuring, Asset-related, and Other Charges."
- (2) For the six months ended June 30, 2018, gain on sales of assets and businesses included a \$42 gain associated with the sale of the Company's Linden, New Jersey site.
- (3) Includes litigation settlements, PFOA drinking water treatment accruals, and other legal charges. For the three and six months ended June 30, 2019, legal charges included \$7 and \$34 in additional charges for the approved final Consent Order associated with certain matters at the Company's Fayetteville, North Carolina facility, which are discussed in further detail in "Note 19 – Commitments and Contingent Liabilities."

**Note 25. Subsequent Events**

***Accounts Receivable Securitization Facility***

On July 12, 2019, the Company, through a wholly-owned special purpose entity (“SPE”), executed an agreement with a bank for an accounts receivable securitization facility (“Securitization Facility”) for the purpose of enhancing the Company’s liquidity. Under the Securitization Facility, certain of the Company’s subsidiaries will sell their accounts receivable to the SPE. In turn, the SPE may transfer undivided ownership interests in such receivables to the bank in exchange for cash. The Securitization Facility permits the SPE to borrow up to a total of \$125, with an option to increase to \$200. The bank has a first priority security interest in all receivables held by the SPE and, as a result, these receivables will not be available to the creditors of the Company or its other subsidiaries.

Because the SPE maintains effective control over the accounts receivable, transfers of the ownership interests to the bank do not meet the criteria to account for the transfers as sales. As a result, the Company will account for transfers under the Securitization Facility as collateralized borrowings. Cash received from the bank will become a short-term obligation of the Company, which will be fully-collateralized by all receivables held by the SPE. The Securitization Facility is subject to interest charges against both the amount of outstanding borrowings and the amount of available but undrawn commitments. The Securitization Facility bears a variable interest rate on outstanding borrowings and a fixed commitment fee on the average daily unused amount of the Securitization Facility. On July 12, 2019, the Company borrowed \$125 pursuant to the Securitization Facility, which was used to pay down the Company’s outstanding revolving loan balance. The \$125 in borrowings under the Company’s Securitization Facility will be classified in its consolidated balance sheets as a component of its current liabilities due to the short-term nature of the obligation.

***Southern Ionics Minerals, LLC Acquisition***

On August 1, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Southern Ionics Minerals, LLC (“SIM”), a privately-held minerals exploration, mining, and manufacturing company headquartered in Jacksonville, Florida, for an estimated total consideration of approximately \$25. SIM mines and processes titanium and zirconium mineral sands, and this acquisition expands Chemours’ flexibility and scalability to internally source ore in the Company’s Titanium Technologies segment. The Company will account for the acquisition of SIM as a business combination, and as such, all assets acquired and liabilities assumed will be recorded at their estimated fair values and any excess of the consideration transferred over the fair value of the net assets acquired will be recognized as goodwill within the Titanium Technologies segment.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Note 26. Guarantor Condensed Consolidating Financial Information**

The following guarantor condensed consolidating financial information is included in accordance with Rule 3-10 of Regulation S-X (“Rule 3-10”) in connection with the subsidiary guarantees of the “Notes” (collectively, the 6.625% senior unsecured notes due May 2023, the 7.000% senior unsecured notes due May 2025, the 4.000% senior unsecured notes due May 2026, which are denominated in euros, and the 5.375% senior unsecured notes due May 2027), in each case, issued by The Chemours Company (“Parent Issuer”). As of the dates indicated, each series of the Notes was fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis, subject to certain exceptions, by the same group of subsidiaries of the Parent Issuer (together, “Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries is 100% owned by the Company. None of the other subsidiaries of the Company, either direct or indirect, guarantee the Notes (together, “Non-Guarantor Subsidiaries”). Pursuant to the indentures governing the Notes, the Guarantor Subsidiaries will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

The following condensed consolidating financial information is presented to comply with the Company’s requirements under Rule 3-10:

- the condensed consolidating statements of comprehensive income for the three and six months ended June 30, 2019 and 2018;
- the condensed consolidating balance sheets at June 30, 2019 and December 31, 2018; and,
- the condensed consolidating statements of cash flows for the six months ended June 30, 2019 and 2018.

The following guarantor condensed consolidating financial information is presented using the equity method of accounting for the Company’s investments in its wholly-owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for the Company’s share of its subsidiaries’ cumulative results of operations, capital contributions, distributions, and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information included herein may not necessarily be indicative of the financial positions, results of operations, or cash flows of the Company’s subsidiaries had they operated as independent entities, and should be read in conjunction with the interim consolidated financial statements and the related notes thereto.

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Condensed Consolidating Statements of Comprehensive Income**

**Three Months Ended June 30, 2019**

	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
Net sales	\$ —	\$ 857	\$ 910	\$ (359)	\$ 1,408
Cost of goods sold	—	736	706	(357)	1,085
Gross profit	—	121	204	(2)	323
Selling, general, and administrative expense	7	100	35	(6)	136
Research and development expense	—	17	2	—	19
Restructuring, asset-related, and other charges	—	7	—	—	7
Total other operating expenses	7	124	37	(6)	162
Equity in earnings of affiliates	—	—	8	—	8
Equity in earnings of subsidiaries	132	—	—	(132)	—
Interest (expense) income, net	(54)	1	1	—	(52)
Intercompany interest income (expense), net	8	4	(12)	—	—
Other income (expense), net	6	32	(16)	(6)	16
<b>Income before income taxes</b>	<b>85</b>	<b>34</b>	<b>148</b>	<b>(134)</b>	<b>133</b>
(Benefit from) provision for income taxes	(11)	14	34	—	37
<b>Net income</b>	<b>96</b>	<b>20</b>	<b>114</b>	<b>(134)</b>	<b>96</b>
<b>Net income attributable to Chemours</b>	<b>\$ 96</b>	<b>\$ 20</b>	<b>\$ 114</b>	<b>\$ (134)</b>	<b>\$ 96</b>
<b>Comprehensive income attributable to Chemours</b>	<b>\$ 108</b>	<b>\$ 20</b>	<b>\$ 131</b>	<b>\$ (151)</b>	<b>\$ 108</b>

**Six Months Ended June 30, 2019**

	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
Net sales	\$ —	\$ 1,734	\$ 1,808	\$ (758)	\$ 2,784
Cost of goods sold	—	1,477	1,443	(755)	2,165
Gross profit	—	257	365	(3)	619
Selling, general, and administrative expense	15	218	74	(15)	292
Research and development expense	—	38	3	—	41
Restructuring, asset-related, and other charges	—	15	—	—	15
Total other operating expenses	15	271	77	(15)	348
Equity in earnings of affiliates	—	—	16	—	16
Equity in earnings (loss) of subsidiaries	259	(2)	—	(257)	—
Interest (expense) income, net	(107)	1	3	—	(103)
Intercompany interest income (expense), net	17	9	(26)	—	—
Other income (expense), net	13	68	(11)	(15)	55
<b>Income before income taxes</b>	<b>167</b>	<b>62</b>	<b>270</b>	<b>(260)</b>	<b>239</b>
(Benefit from) provision for income taxes	(22)	13	59	—	50
<b>Net income</b>	<b>189</b>	<b>49</b>	<b>211</b>	<b>(260)</b>	<b>189</b>
<b>Net income attributable to Chemours</b>	<b>\$ 189</b>	<b>\$ 49</b>	<b>\$ 211</b>	<b>\$ (260)</b>	<b>\$ 189</b>
<b>Comprehensive income attributable to Chemours</b>	<b>\$ 222</b>	<b>\$ 49</b>	<b>\$ 242</b>	<b>\$ (291)</b>	<b>\$ 222</b>

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Condensed Consolidating Statements of Comprehensive Income**

**Three Months Ended June 30, 2018**

	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
Net sales	\$ —	\$ 1,067	\$ 1,215	\$ (466)	\$ 1,816
Cost of goods sold	—	838	885	(464)	1,259
Gross profit	—	229	330	(2)	557
Selling, general, and administrative expense	14	115	38	(6)	161
Research and development expense	—	18	2	—	20
Restructuring, asset-related, and other charges	—	10	—	—	10
Total other operating expenses	14	143	40	(6)	191
Equity in earnings of affiliates	—	—	10	—	10
Equity in earnings of subsidiaries	346	3	—	(349)	—
Interest (expense) income, net	(51)	—	3	—	(48)
Intercompany interest income (expense), net	8	3	(11)	—	—
Loss on extinguishment of debt	(38)	—	—	—	(38)
Other income, net	9	20	9	(5)	33
<b>Income before income taxes</b>	<b>260</b>	<b>112</b>	<b>301</b>	<b>(350)</b>	<b>323</b>
(Benefit from) provision for income taxes	(21)	11	50	1	41
<b>Net income</b>	<b>281</b>	<b>101</b>	<b>251</b>	<b>(351)</b>	<b>282</b>
Less: Net income attributable to non-controlling interests	—	—	1	—	1
<b>Net income attributable to Chemours</b>	<b>\$ 281</b>	<b>\$ 101</b>	<b>\$ 250</b>	<b>\$ (351)</b>	<b>\$ 281</b>
<b>Comprehensive income attributable to Chemours</b>	<b>\$ 179</b>	<b>\$ 101</b>	<b>\$ 111</b>	<b>\$ (212)</b>	<b>\$ 179</b>

**Six Months Ended June 30, 2018**

	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
Net sales	\$ —	\$ 2,084	\$ 2,389	\$ (927)	\$ 3,546
Cost of goods sold	—	1,634	1,756	(938)	2,452
Gross profit	—	450	633	11	1,094
Selling, general, and administrative expense	24	218	78	(16)	304
Research and development expense	—	37	3	—	40
Restructuring, asset-related, and other charges	—	19	1	—	20
Total other operating expenses	24	274	82	(16)	364
Equity in earnings of affiliates	—	—	22	—	22
Equity in earnings of subsidiaries	677	3	—	(680)	—
Interest (expense) income, net	(108)	2	6	—	(100)
Intercompany interest income (expense), net	21	4	(25)	—	—
Loss on extinguishment of debt	(38)	—	—	—	(38)
Other income (expense), net	18	93	(7)	(14)	90
<b>Income before income taxes</b>	<b>546</b>	<b>278</b>	<b>547</b>	<b>(667)</b>	<b>704</b>
(Benefit from) provision for income taxes	(32)	61	96	—	125
<b>Net income</b>	<b>578</b>	<b>217</b>	<b>451</b>	<b>(667)</b>	<b>579</b>
Less: Net income attributable to non-controlling interests	—	—	1	—	1
<b>Net income attributable to Chemours</b>	<b>\$ 578</b>	<b>\$ 217</b>	<b>\$ 450</b>	<b>\$ (667)</b>	<b>\$ 578</b>
<b>Comprehensive income attributable to Chemours</b>	<b>\$ 551</b>	<b>\$ 217</b>	<b>\$ 412</b>	<b>\$ (629)</b>	<b>\$ 551</b>

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Condensed Consolidating Balance Sheets**

	<b>June 30, 2019</b>				
	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
<b>Assets</b>					
Current assets:					
Cash and cash equivalents	\$ —	\$ 124	\$ 506	\$ —	\$ 630
Accounts and notes receivable, net	—	317	562	—	879
Intercompany receivables	2	897	416	(1,315)	—
Inventories	—	650	688	(88)	1,250
Prepaid expenses and other	—	45	23	5	73
<b>Total current assets</b>	<b>2</b>	<b>2,033</b>	<b>2,195</b>	<b>(1,398)</b>	<b>2,832</b>
Property, plant, and equipment	—	7,042	2,217	—	9,259
Less: Accumulated depreciation	—	(4,639)	(1,129)	—	(5,768)
Property, plant, and equipment, net	—	2,403	1,088	—	3,491
Operating lease right-of-use assets	—	298	24	—	322
Goodwill and other intangible assets, net	—	164	14	—	178
Investments in affiliates	—	—	177	—	177
Investments in subsidiaries	4,671	—	—	(4,671)	—
Intercompany notes receivable	1,150	—	—	(1,150)	—
Other assets	15	154	284	(20)	433
<b>Total assets</b>	<b>\$ 5,838</b>	<b>\$ 5,052</b>	<b>\$ 3,782</b>	<b>\$ (7,239)</b>	<b>\$ 7,433</b>
<b>Liabilities</b>					
Current liabilities:					
Accounts payable	\$ —	\$ 579	\$ 377	\$ —	\$ 956
Current maturities of long-term debt	13	—	5	—	18
Intercompany payables	927	123	265	(1,315)	—
Other accrued liabilities	21	309	145	(1)	474
<b>Total current liabilities</b>	<b>961</b>	<b>1,011</b>	<b>792</b>	<b>(1,316)</b>	<b>1,448</b>
Long-term debt, net	4,047	86	57	—	4,190
Operating lease liabilities	—	250	15	—	265
Intercompany notes payable	—	—	1,150	(1,150)	—
Deferred income taxes	7	133	87	(13)	214
Other liabilities	—	408	79	—	487
<b>Total liabilities</b>	<b>5,015</b>	<b>1,888</b>	<b>2,180</b>	<b>(2,479)</b>	<b>6,604</b>
Commitments and contingent liabilities					
<b>Equity</b>					
Total Chemours stockholders' equity	823	3,164	1,596	(4,760)	823
Non-controlling interests	—	—	6	—	6
<b>Total equity</b>	<b>823</b>	<b>3,164</b>	<b>1,602</b>	<b>(4,760)</b>	<b>829</b>
<b>Total liabilities and equity</b>	<b>\$ 5,838</b>	<b>\$ 5,052</b>	<b>\$ 3,782</b>	<b>\$ (7,239)</b>	<b>\$ 7,433</b>



**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Condensed Consolidating Balance Sheets**

**December 31, 2018**

	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
<b>Assets</b>					
Current assets:					
Cash and cash equivalents	\$ —	\$ 239	\$ 962	\$ —	\$ 1,201
Accounts and notes receivable, net	—	297	564	—	861
Intercompany receivables	2	1,057	91	(1,150)	—
Inventories	—	483	749	(85)	1,147
Prepaid expenses and other	—	58	26	—	84
Total current assets	2	2,134	2,392	(1,235)	3,293
Property, plant, and equipment	—	6,870	2,122	—	8,992
Less: Accumulated depreciation	—	(4,591)	(1,110)	—	(5,701)
Property, plant, and equipment, net	—	2,279	1,012	—	3,291
Goodwill and other intangible assets, net	—	167	14	—	181
Investments in affiliates	—	—	160	—	160
Investments in subsidiaries	4,487	11	—	(4,498)	—
Intercompany notes receivable	1,150	—	—	(1,150)	—
Other assets	17	154	274	(8)	437
<b>Total assets</b>	<b>\$ 5,656</b>	<b>\$ 4,745</b>	<b>\$ 3,852</b>	<b>\$ (6,891)</b>	<b>\$ 7,362</b>
<b>Liabilities</b>					
Current liabilities:					
Accounts payable	\$ —	\$ 637	\$ 500	\$ —	\$ 1,137
Current maturities of long-term debt	13	—	—	—	13
Intercompany payables	698	92	360	(1,150)	—
Other accrued liabilities	21	341	198	(1)	559
Total current liabilities	732	1,070	1,058	(1,151)	1,709
Long-term debt, net	3,902	57	—	—	3,959
Intercompany notes payable	—	—	1,150	(1,150)	—
Deferred income taxes	8	143	82	(16)	217
Other liabilities	—	372	85	—	457
Total liabilities	4,642	1,642	2,375	(2,317)	6,342
Commitments and contingent liabilities					
<b>Equity</b>					
Total Chemours stockholders' equity	1,014	3,103	1,471	(4,574)	1,014
Non-controlling interests	—	—	6	—	6
Total equity	1,014	3,103	1,477	(4,574)	1,020
<b>Total liabilities and equity</b>	<b>\$ 5,656</b>	<b>\$ 4,745</b>	<b>\$ 3,852</b>	<b>\$ (6,891)</b>	<b>\$ 7,362</b>

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Condensed Consolidating Statements of Cash Flows**

	<b>Six Months Ended June 30, 2019</b>				
	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
<b>Cash flows from operating activities</b>					
Cash provided by (used for) operating activities	\$ 56	\$ 23	\$ (3)	\$ (114)	\$ (38)
<b>Cash flows from investing activities</b>					
Purchases of property, plant, and equipment	—	(214)	(43)	—	(257)
Intercompany investing activities	—	75	(294)	219	—
Proceeds from sales of assets and businesses, net	—	1	—	—	1
Cash used for investing activities	—	(138)	(337)	219	(256)
<b>Cash flows from financing activities</b>					
Proceeds from revolving loan	150	—	—	—	150
Debt repayments	(6)	—	—	—	(6)
Purchases of treasury stock, at cost	(322)	—	—	—	(322)
Intercompany financing activities	227	—	(122)	(105)	—
Proceeds from exercised stock options, net	8	—	—	—	8
Payments related to tax withholdings on vested stock awards	(30)	—	—	—	(30)
Payments of dividends	(83)	—	—	—	(83)
Cash used for financing activities	(56)	—	(122)	(105)	(283)
Effect of exchange rate changes on cash and cash equivalents	—	—	6	—	6
<b>Decrease in cash and cash equivalents</b>	<b>—</b>	<b>(115)</b>	<b>(456)</b>	<b>—</b>	<b>(571)</b>
<b>Cash and cash equivalents at January 1,</b>	<b>—</b>	<b>239</b>	<b>962</b>	<b>—</b>	<b>1,201</b>
<b>Cash and cash equivalents at June 30,</b>	<b>\$ —</b>	<b>\$ 124</b>	<b>\$ 506</b>	<b>\$ —</b>	<b>\$ 630</b>

**The Chemours Company**  
**Notes to the Interim Consolidated Financial Statements (Unaudited)**  
*(Dollars in millions, except per share amounts)*

**Condensed Consolidating Statements of Cash Flows**

**Six Months Ended June 30, 2018**

	<b>Parent Issuer</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Eliminations and Adjustments</b>	<b>Consolidated</b>
<b>Cash flows from operating activities</b>					
Cash (used for) provided by operating activities	\$ (95)	\$ 319	\$ 315	\$ —	\$ 539
<b>Cash flows from investing activities</b>					
Purchases of property, plant, and equipment	—	(168)	(60)	—	(228)
Acquisition of business, net	—	(37)	—	—	(37)
Proceeds from sales of assets and businesses, net	—	41	—	—	41
Intercompany investing activities	—	(736)	—	736	—
Foreign exchange contract settlements, net	—	(6)	—	—	(6)
Cash used for investing activities	—	(906)	(60)	736	(230)
<b>Cash flows from financing activities</b>					
Proceeds from issuance of debt, net	520	—	—	—	520
Debt repayments	(672)	—	—	—	(672)
Payments related to extinguishment of debt	(29)	—	—	—	(29)
Payments of debt issuance costs	(12)	—	—	—	(12)
Purchases of treasury stock, at cost	(394)	—	—	—	(394)
Intercompany financing activities	736	—	—	(736)	—
Proceeds from exercised stock options, net	13	—	—	—	13
Payments related to tax withholdings on vested stock awards	(6)	—	—	—	(6)
Payments of dividends	(61)	—	—	—	(61)
Cash provided by (used for) financing activities	95	—	—	(736)	(641)
Effect of exchange rate changes on cash and cash equivalents	—	—	(7)	—	(7)
<b>(Decrease) increase in cash and cash equivalents</b>	<b>—</b>	<b>(587)</b>	<b>248</b>	<b>—</b>	<b>(339)</b>
<b>Cash and cash equivalents at January 1,</b>	<b>—</b>	<b>761</b>	<b>795</b>	<b>—</b>	<b>1,556</b>
<b>Cash and cash equivalents at June 30,</b>	<b>\$ —</b>	<b>\$ 174</b>	<b>\$ 1,043</b>	<b>\$ —</b>	<b>\$ 1,217</b>

## Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") supplements the unaudited Interim Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations for the periods presented. Unless the context otherwise requires, references herein to "The Chemours Company," "Chemours," "the Company," "our Company," "we," "us," and "our" refer to The Chemours Company and its consolidated subsidiaries. References herein to "DuPont" refer to E. I. du Pont de Nemours and Company, a Delaware corporation.

This MD&A should be read in conjunction with the unaudited Interim Consolidated Financial Statements and the related notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited Consolidated Financial Statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words "believe," "expect," "anticipate," "plan," "estimate," "target," "project," and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements.

Our forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties, and other factors discussed in the Forward-looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, 2018, and otherwise as discussed in this report and our Annual Report on Form 10-K. We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.

### Overview

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including plastics and coatings, refrigeration and air conditioning, general industrial, electronics, mining, and oil refining. Our principal products include refrigerants, industrial fluoropolymer resins, sodium cyanide, performance chemicals and intermediates, and titanium dioxide ("TiO<sub>2</sub>") pigment. We manage and report our operating results through three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. Our Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. Our Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications. Our Titanium Technologies segment is a leading, global provider of TiO<sub>2</sub> pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

We are committed to creating value for our customers and stakeholders through the reliable delivery of high-quality products and services around the world. To achieve this goal, we have a global team dedicated to upholding our five core values: (i) **customer centricity** – driving customer growth, and our own, by understanding our customers' needs and building long-lasting relationships with them; (ii) **refreshing simplicity** – cutting complexity by investing in what matters, and getting results faster; (iii) **collective entrepreneurship** – empowering our employees to act like they own our business, while embracing the power of inclusion and teamwork; (iv) **safety obsession** – living our steadfast belief that a safe workplace is a profitable workplace; and, (v) **unshakable integrity** – doing what's right for our customers, colleagues, and communities – always.

Additionally, our Corporate Responsibility commitment focuses on three key principles – inspired people, a shared planet, and an evolved portfolio – in an effort to achieve, among other goals, increased diversity and inclusion in our global workforce, increased sustainability of our products, and becoming carbon positive. We call this responsible chemistry – it is rooted in who we are, and we expect that our Corporate Responsibility commitment will drive sustainable, long-term earnings growth.

**Recent Developments**

**Capital Allocation**

We returned \$405 million to our shareholders during the six months ended June 30, 2019 through the purchase of \$322 million of our issued and outstanding common stock under our share repurchase program, and the payment of \$83 million in dividends.

**Accounts Receivable Securitization Facility**

In July 2019, we, through a wholly-owned special purpose entity, entered into an accounts receivable securitization facility to enhance our liquidity. In connection with this arrangement, we borrowed the full \$125 million of available capacity under the accounts receivable securitization facility, which was used to pay down our outstanding revolving loan balance.

**Results of Operations and Business Highlights**

**Results of Operations**

The following table sets forth our results of operations for the three and six months ended June 30, 2019 and 2018.

<i>(Dollars in millions, except per share amounts)</i>	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Net sales	\$ 1,408	\$ 1,816	\$ 2,784	\$ 3,546
Cost of goods sold	1,085	1,259	2,165	2,452
Gross profit	323	557	619	1,094
Selling, general, and administrative expense	136	161	292	304
Research and development expense	19	20	41	40
Restructuring, asset-related, and other charges	7	10	15	20
Total other operating expenses	162	191	348	364
Equity in earnings of affiliates	8	10	16	22
Interest expense, net	(52)	(48)	(103)	(100)
Loss on extinguishment of debt	—	(38)	—	(38)
Other income, net	16	33	55	90
<b>Income before income taxes</b>	<b>133</b>	<b>323</b>	<b>239</b>	<b>704</b>
Provision for income taxes	37	41	50	125
<b>Net income</b>	<b>96</b>	<b>282</b>	<b>189</b>	<b>579</b>
Less: Net income attributable to non-controlling interests	—	1	—	1
<b>Net income attributable to Chemours</b>	<b>\$ 96</b>	<b>\$ 281</b>	<b>\$ 189</b>	<b>\$ 578</b>
<b>Per share data</b>				
Basic earnings per share of common stock	\$ 0.58	\$ 1.58	\$ 1.14	\$ 3.21
Diluted earnings per share of common stock	0.57	1.53	1.12	3.11

**Net Sales**

The following table sets forth the impact of price, volume, and currency on our net sales for the three and six months ended June 30, 2019, compared with the same periods in 2018.

<b>Change in net sales from prior period</b>	<b>Three Months Ended June 30, 2019</b>	<b>Six Months Ended June 30, 2019</b>
Price	(1)%	—%
Volume	(20)%	(20)%
Currency	(1)%	(1)%
<b>Total change in net sales</b>	<b>(22)%</b>	<b>(21)%</b>

Our net sales decreased by \$408 million (or 22%) to \$1.4 billion for the three months ended June 30, 2019, compared with net sales of \$1.8 billion for the same period in 2018. The components of the decrease in our net sales by segment for the three months ended June 30, 2019 were as follows: in our Fluoroproducts segment, volume was down 7%, while price and unfavorable currency movements each added a 2% headwind to segment net sales; in our Chemical Solutions segment, volume was down 19%, which was partially offset by a 4% increase in price; and, in our Titanium Technologies segment, volume was down 33%, while unfavorable currency movements added a 1% headwind to segment net sales.

Our net sales decreased by \$762 million (or 21%) to \$2.8 billion for the six months ended June 30, 2019, compared with net sales of \$3.5 billion for the same period in 2018. The components of the decrease in our net sales by segment for the six months ended June 30, 2019 were as follows: in our Fluoroproducts segment, volume was down 6%, while unfavorable currency movements and price added 2% and 1% headwinds to segment net sales, respectively; in our Chemical Solutions segment, volume was down 14% and unfavorable currency movements added a 1% headwind to segment net sales, while a 4% increase in price provided a partial offset; and, in our Titanium Technologies segment, volume was down 34% and unfavorable currency movements added a 1% headwind to segment net sales.

The drivers of these changes for each of our segments are discussed further under the heading “Segment Reviews,” which follows our “Results of Operations and Business Highlights” in this MD&A.

**Cost of Goods Sold**

Our cost of goods sold (“COGS”) decreased by \$174 million (or 14%) and \$287 million (or 12%) to \$1.1 billion and \$2.2 billion for the three and six months ended June 30, 2019, respectively, compared with COGS of \$1.3 billion and \$2.5 billion for the same periods in 2018. The decreases in our COGS for the three and six months ended June 30, 2019 were primarily attributable to lower net sales volume, which was partially offset by margin compression resulting from lower volume.

**Selling, General, and Administrative Expense**

Our selling, general, and administrative (“SG&A”) expense decreased by \$25 million (or 16%) to \$136 million for the three months ended June 30, 2019, compared with SG&A expense of \$161 million for the same period in 2018. The decrease in our SG&A expense for the three months ended June 30, 2019 was primarily attributable to lower costs for certain legal matters, as well as costs incurred in the second quarter of 2018 for our debt transactions. These costs were not repeated in the second quarter of 2019.

Our SG&A expense decreased by \$12 million (or 4%) to \$292 million for the six months ended June 30, 2019, compared with SG&A expense of \$304 million for the same period in 2018. The decrease in our SG&A expense for the six months ended June 30, 2019 was primarily attributable to lower performance-related compensation and costs incurred for our 2018 debt transactions that were not repeated in 2019. These decreases were partially offset by increased legal costs accrued during the first quarter of 2019 in connection with the approved final Consent Order to settle certain litigation and other matters at our Fayetteville, North Carolina facility.

**Research and Development Expense**

Our research and development expense was largely unchanged at \$19 million and \$20 million, and \$41 million and \$40 million for the three and six months ended June 30, 2019 and 2018, respectively.

***Restructuring, Asset-Related, and Other Charges***

Our restructuring, asset-related, and other charges decreased by \$3 million (or 30%) and \$5 million (or 25%) to \$7 million and \$15 million for the three and six months ended June 30, 2019, respectively, compared with restructuring, asset-related, and other charges of \$10 million and \$20 million for the same periods in 2018. Our restructuring, asset-related, and other charges for the three and six months ended June 30, 2019 were primarily attributable to decommissioning and dismantling-related charges associated with the demolition and removal of certain unused buildings at our Chambers Works site in Deepwater, New Jersey. Our restructuring, asset-related, and other charges for the three and six months ended June 30, 2018 were primarily attributable to continued progress on our business process and information technology outsourcing efforts, as well as additional severance accruals under our 2017 restructuring program.

***Equity in Earnings of Affiliates***

Our equity in earnings of affiliates decreased by \$2 million (or 20%) and \$6 million (or 27%) to \$8 million and \$16 million for the three and six months ended June 30, 2019, respectively, compared with equity in earnings of affiliates of \$10 million and \$22 million for the same periods in 2018. The decreases in our equity in earnings of affiliates for the three and six months ended June 30, 2019 were primarily attributable to decreased profitability for our equity method investees in the Fluoroproducts segment.

***Interest Expense, Net***

Our interest expense, net increased by \$4 million (or 8%) and \$3 million (or 3%) to \$52 million and \$103 million for the three and six months ended June 30, 2019, respectively, compared with interest expense, net of \$48 million and \$100 million for the same periods in 2018. The increase in our interest expense, net for the three months ended June 30, 2019 was primarily attributable to lower amounts of interest income and capitalized interest due to lower cash and cash equivalents balances and the completion or stoppage of certain of our large-scale construction projects, respectively. The increase in our interest expense, net for the six months ended June 30, 2019 was primarily attributable to lower amounts of interest income and capitalized interest due to the aforementioned reasons, which more than offset the impact of any reduced interest costs resulting from our 2018 debt transactions.

***Loss on Extinguishment of Debt***

We incurred a loss on extinguishment of debt of \$38 million for the three and six months ended June 30, 2018 in connection with our 2018 debt transactions.

***Other Income, Net***

Our other income, net decreased by \$17 million (or 52%) and \$35 million (or 39%) to \$16 million and \$55 million for the three and six months ended June 30, 2019, respectively, compared with other income, net of \$33 million and \$90 million for the same periods in 2018. The decrease in our other income, net for the three months ended June 30, 2019 was primarily attributable to lower European Union (“EU”) fluorinated greenhouse gas (“F-gas”) quota authorization sales, lower non-operating pension and other post-retirement employee benefit income, and changes in net exchange gains and losses. The decrease in our other income, net for the six months ended June 30, 2019 was primarily attributable to a \$42 million gain on our sale of land in Linden, New Jersey during the first quarter of 2018, which was not repeated in 2019. This decrease was partially offset by an increase in EU F-gas quota authorization sales for the six months ended June 30, 2019.

***Provision for Income Taxes***

Our provisions for income taxes were \$37 million and \$50 million for the three and six months ended June 30, 2019, which represented effective tax rates of 28% and 21%, respectively, compared with provisions for income taxes of \$41 million and \$125 million for the same periods in 2018, which represented effective tax rates of 13% and 18%, respectively. The change in our effective tax rate for the three months ended June 30, 2019 was primarily attributable to \$6 million of lower income tax benefits related to windfalls on our share-based payments, \$8 million of additional income tax expense associated with the recognition of a valuation allowance on the deferred tax assets of a certain foreign subsidiary, and the geographic mix of our earnings. The change in our effective tax rate for the six months ended June 30, 2019 was primarily attributable to \$4 million of lower income tax benefits related to windfalls on our share-based payments, \$8 million of additional income tax expense associated with the recognition of a valuation allowance on the deferred tax assets of a certain foreign subsidiary, and the geographic mix of our earnings.

**Segment Reviews**

Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is the primary measure of segment performance used by our Chief Operating Decision Maker (“CODM”) and is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represents the component of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of assets and businesses; and,
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

A reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three and six months ended June 30, 2019 and 2018 is included in the “Non-GAAP Financial Measures” section of this MD&A.

The following table sets forth our Adjusted EBITDA by segment for the three and six months ended June 30, 2019 and 2018.

<i>(Dollars in millions)</i>	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Fluoroproducts	\$ 180	\$ 230	\$ 339	\$ 437
Chemical Solutions	16	16	31	26
Titanium Technologies	127	295	253	589
Corporate and Other	(40)	(44)	(78)	(87)
<b>Total Adjusted EBITDA</b>	<b>\$ 283</b>	<b>\$ 497</b>	<b>\$ 545</b>	<b>\$ 965</b>




Fluoroproducts

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Fluoroproducts segment for the three and six months ended June 30, 2019 and 2018.

**Fluoroproducts Segment Results of Operations  
Three Months Ended June 30,**



**Fluoroproducts Segment Results of Operations  
Six Months Ended June 30,**



	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<i>(Dollars in millions)</i>				
Segment net sales	\$ 711	\$ 801	\$ 1,398	\$ 1,532
Adjusted EBITDA	180	230	339	437
Adjusted EBITDA margin	25%	29%	24%	29%

## The Chemours Company

The following table sets forth the impacts of price, volume, and currency on our Fluoroproducts segment's net sales for the three and six months ended June 30, 2019, compared with the same periods in 2018.

<b>Change in segment net sales from prior period</b>	<b>Three Months Ended June 30, 2019</b>	<b>Six Months Ended June 30, 2019</b>
Price	(2)%	(1)%
Volume	(7)%	(6)%
Currency	(2)%	(2)%
<b>Total change in segment net sales</b>	<b>(11)%</b>	<b>(9)%</b>

### *Segment Net Sales*

Our Fluoroproducts segment's net sales decreased by \$90 million (or 11%) to \$711 million for the three months ended June 30, 2019, compared with segment net sales of \$801 million for the same period in 2018. The decrease in segment net sales for the three months ended June 30, 2019 was primarily attributable to a 7% decrease in volume, due to the following: illegal imports of legacy hydrofluorocarbon ("HFC") refrigerants into the EU in violation of the region's F-gas regulations, which impacted both volume and price during the quarter; lower demand for our legacy base refrigerants; and, market softness. These volume decreases were partially offset by a volume increase from the continued adoption of Opteon™ products and applications development for our fluoropolymers products. We also experienced a 2% decrease in price, due to the aforementioned global price pressures from illegal imports impacting our refrigerants products, which was partially offset by higher average selling prices and the product mix of sales for our fluoropolymers products. Unfavorable currency movements added a 2% headwind to the segment's net sales during the quarter.

Our Fluoroproducts segment's net sales decreased by \$134 million (or 9%) to \$1.4 billion for the six months ended June 30, 2019, compared with segment net sales of \$1.5 billion for the same period in 2018. The decrease in segment net sales for the six months ended June 30, 2019 was primarily attributable to a 6% decrease in volume, due to the following: illegal imports of legacy HFC refrigerants into the EU, which impacted both volume and price year-to-date; lower demand for our legacy base refrigerants; and, market softness. These volume decreases were partially offset by a volume increase from the continued adoption of Opteon™ products and applications development for our fluoropolymers products. Unfavorable currency movements added a 2% headwind to the segment's net sales year-to-date. We also experienced a 1% decrease in price, due to the aforementioned global price pressures from illegal imports impacting our refrigerants products, which was partially offset by higher average selling prices and the product mix of sales for our fluoropolymers products.


### *Adjusted EBITDA and Adjusted EBITDA Margin*

For the three months ended June 30, 2019, segment Adjusted EBITDA decreased by \$50 million (or 22%) to \$180 million and Adjusted EBITDA margin decreased by approximately 400 basis points to 25%, compared with segment Adjusted EBITDA of \$230 million and Adjusted EBITDA margin of 29% for the same period in 2018. For the six months ended June 30, 2019, segment Adjusted EBITDA decreased by \$98 million (or 22%) to \$339 million and Adjusted EBITDA margin decreased by approximately 500 basis points to 24%, compared with segment Adjusted EBITDA of \$437 million and Adjusted EBITDA margin of 29% for the same period in 2018. These decreases were primarily attributable to the aforementioned decreases in volume, price, and unfavorable currency movements. Additionally, we experienced increased costs of approximately \$30 million for the six months ended June 30, 2019 due to the start-up of our new Opteon™ refrigerants facility in Corpus Christi, Texas, and unplanned outages at our Louisville, Kentucky facility in the first quarter of 2019. These decreases were partially offset by an \$18 million increase in EU F-gas quota authorization sales for the six months ended June 30, 2019.

Chemical Solutions

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Chemical Solutions segment for the three and six months ended June 30, 2019 and 2018.

**Chemical Solutions Segment Results of Operations  
Three Months Ended June 30,**



**Chemical Solutions Segment Results of Operations  
Six Months Ended June 30,**



(Dollars in millions)

	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
Segment net sales	\$ 130	\$ 153	\$ 264	\$ 297
Adjusted EBITDA	16	16	31	26
Adjusted EBITDA margin	12%	10%	12%	9%

## The Chemours Company

The following table sets forth the impacts of price, volume, and currency on our Chemical Solutions segment's net sales for the three and six months ended June 30, 2019, compared with the same periods in 2018.

<b>Change in segment net sales from prior period</b>	<b>Three Months Ended June 30, 2019</b>	<b>Six Months Ended June 30, 2019</b>
Price	4%	4%
Volume	(19)%	(14)%
Currency	—%	(1)%
<b>Total change in segment net sales</b>	<b>(15)%</b>	<b>(11)%</b>

### *Segment Net Sales*

Our Chemical Solutions segment's net sales decreased by \$23 million (or 15%) to \$130 million for the three months ended June 30, 2019, compared with segment net sales of \$153 million for the same period in 2018. The decrease in segment net sales for the three months ended June 30, 2019 was primarily attributable to a 19% decrease in volume, due to a scheduled plant turnaround and operational issues at a key customer mine in Mining Solutions and lower demand for certain of our Performance Chemicals and Intermediates products. This decrease was partially offset by a 4% increase in price, due to higher average selling prices in Mining Solutions and several Performance Chemicals and Intermediates products.



Our Chemical Solutions segment's net sales decreased by \$33 million (or 11%) to \$264 million for the six months ended June 30, 2019, compared with segment net sales of \$297 million for the same period in 2018. The decrease in segment net sales for the six months ended June 30, 2019 was primarily attributable to a 14% decrease in volume, due to a scheduled plant turnaround and operational issues at a key customer mine in Mining Solutions and lower demand for certain of our Performance Chemicals and Intermediates products, and a 1% headwind from unfavorable currency movements. These decreases were partially offset by a 4% increase in price, due to higher average selling prices in Mining Solutions and several Performance Chemicals and Intermediates products.

### *Adjusted EBITDA and Adjusted EBITDA Margin*

For the three months ended June 30, 2019, segment Adjusted EBITDA increased by less than \$1 million (or 4%) to \$16 million and Adjusted EBITDA margin increased by approximately 200 basis points to 12%, compared with segment Adjusted EBITDA of \$16 million and Adjusted EBITDA margin of 10% for the same period in 2018. For the six months ended June 30, 2019, segment Adjusted EBITDA increased by \$5 million (or 19%) to \$31 million and Adjusted EBITDA margin increased by approximately 300 basis points to 12%, compared with segment Adjusted EBITDA of \$26 million and Adjusted EBITDA margin of 9% for the same period in 2018. These increases were primarily attributable to the aforementioned increases in price, product mix, and other income amounts, as well as lower costs associated with certain of our capital projects.

**Titanium Technologies**

The following chart sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Titanium Technologies segment for the three and six months ended June 30, 2019 and 2018.



	<b>Three Months Ended June 30,</b>		<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>	<b>2019</b>	<b>2018</b>
<i>(Dollars in millions)</i>				
Segment net sales	\$ 567	\$ 862	\$ 1,122	\$ 1,717
Adjusted EBITDA	127	295	253	589
Adjusted EBITDA margin	22%	34%	23%	34%

The following table sets forth the impacts of price, volume, and currency on our Titanium Technologies segment's net sales for the three and six months ended June 30, 2019, compared with the same periods in 2018.

<b>Change in segment net sales from prior period</b>	<b>Three Months Ended June 30, 2019</b>	<b>Six Months Ended June 30, 2019</b>
Price	—%	—%
Volume	(33)%	(34)%
Currency	(1)%	(1)%
<b>Total change in segment net sales</b>	<b>(34)%</b>	<b>(35)%</b>

#### *Segment Net Sales*

Our Titanium Technologies segment's net sales decreased by \$295 million (or 34%) to \$567 million for the three months ended June 30, 2019, compared with segment net sales of \$862 million for the same period in 2018. The decrease in segment net sales for the three months ended June 30, 2019 was primarily attributable to a 33% decrease in volume, due to lower market demand and share loss. Unfavorable currency movements added another 1% of headwind to segment net sales, while price remained stable as a result of the implementation of our Ti-Pure™ Value Stabilization ("TVS") strategy.

Our Titanium Technologies segment's net sales decreased by \$595 million (or 35%) to \$1.1 billion for the six months ended June 30, 2019, compared with segment net sales of \$1.7 billion for the same period in 2018. The decrease in segment net sales for the six months ended June 30, 2019 was primarily attributable to a 34% decrease in volume, due to lower market demand and share loss, and a 1% headwind from unfavorable currency movements. Price remained stable as a result of the implementation of our TVS strategy.

#### *Adjusted EBITDA and Adjusted EBITDA Margin*

For the three months ended June 30, 2019, segment Adjusted EBITDA decreased by \$168 million (or 57%) to \$127 million and Adjusted EBITDA margin decreased by approximately 1,200 basis points to 22%, compared with segment Adjusted EBITDA of \$295 million and Adjusted EBITDA margin of 34% for the same period in 2018. For the six months ended June 30, 2019, segment Adjusted EBITDA decreased by \$336 million (or 57%) to \$253 million and Adjusted EBITDA margin decreased by approximately 1,100 basis points to 23%, compared with segment Adjusted EBITDA of \$589 million and Adjusted EBITDA margin of 34% for the same period in 2018. These decreases were primarily attributable to the aforementioned decreases in volume and unfavorable currency movements, as well as margin compression due to decreased volume and higher costs for certain raw materials.

#### *Corporate and Other*

Corporate and Other costs decreased by \$4 million (or 9%) and \$9 million (or 10%) to \$40 million and \$78 million for the three and six months ended June 30, 2019, respectively, compared with Corporate and Other costs of \$44 million and \$87 million for the same periods in 2018. The decrease in our Corporate and Other costs for the three months ended June 30, 2019 was primarily attributable to lower costs for certain legacy environmental and legal matters. The decrease in our Corporate and Other costs for the six months ended June 30, 2019 was primarily attributable to lower costs for certain legacy environmental and legal matters, as well as lower performance-related compensation.

#### **2019 Outlook**

Our 2019 results will be driven by the following expectations: (i) 2019 volume for our Titanium Technologies segment will be below 2018 volume levels as we execute our TVS strategy; (ii) there will be continued transition to Opteon™ refrigerants in our Fluoroproducts segment, which will be offset by the impacts of illegal imports of legacy HFC refrigerants into the EU in violation of the region's F-gas regulations; and, (iii) there will be continued demand for Mining Solutions products in our Chemical Solutions segment. We expect that our capital expenditures will be approximately \$500 million. Our outlook for 2019 reflects our current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. These expectations are subject to numerous risks, including, but not limited to, those described in *Item 1A – Risk Factors* contained in our Annual Report on Form 10-K for the year ended December 31, 2018.

## Liquidity and Capital Resources

Our primary sources of liquidity are cash generated from operations, available cash, receivables securitization, and borrowings under our debt financing arrangements, which are described in further detail in “Note 17 – Debt” to the *Interim Consolidated Financial Statements* and “Note 19 – Debt” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend, and contractual obligations. Our financial policy seeks to: (i) selectively invest in organic and inorganic growth to enhance our portfolio, including certain strategic capital investments; (ii) return cash to shareholders through dividends and share repurchases; and, (iii) maintain appropriate leverage by using free cash flows to repay outstanding borrowings. Subject to approval by our board of directors, we may raise additional capital or borrowings from time to time, or seek to refinance our existing debt. There can be no assurances that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materially impacted by market conditions. Further, the decision to refinance our existing debt is based on a number of factors, including general market conditions and our ability to refinance on attractive terms at any given point in time. Any attempts to raise additional capital or borrowings or refinance our existing debt could cause us to incur significant charges. Such charges could have a material impact on our financial position, results of operations, or cash flows.

Our operating cash flow generation is driven by, among other things, the general global economic conditions at any point in time and their resulting impact on demand for our products, raw materials and energy prices, and industry-specific issues, such as production capacity and utilization. We have generated strong operating cash flows through various industry and economic cycles, evidencing the operating strength of our businesses.

We anticipate making significant payments for interest, capital expenditures, environmental remediation costs and investments, dividends, and other actions over the next 12 months, which we expect to fund through cash generated from operations, available cash, receivables securitization, and borrowings. We further anticipate that our operations and existing debt financing arrangements will provide us with sufficient liquidity over the next 12 months. The availability under our revolving credit facility is subject to the last 12 months of consolidated EBITDA, as defined in our amended and restated credit agreement, which is discussed further in in “Note 17 – Debt” to the *Interim Consolidated Financial Statements* and “Note 19 – Debt” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018.

At June 30, 2019, we had total cash and cash equivalents of \$630 million, of which, \$506 million was held by our foreign subsidiaries, and certain of these foreign subsidiaries’ earnings are indefinitely reinvested. All of the cash and cash equivalents held by our foreign subsidiaries is readily convertible into currencies used in our operations, including the U.S. dollar. The cash and earnings of our foreign subsidiaries are generally used to finance their operations and capital expenditures. At June 30, 2019, management believed that sufficient liquidity was available in the U.S., which includes borrowing capacity under our revolving credit facility, and it is our intention to indefinitely reinvest the historical pre-2018 earnings of our foreign subsidiaries. Beginning in 2018, management asserts that only certain foreign subsidiaries are indefinitely reinvested. See “Note 9 – Income Taxes” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018 for further information related to our income tax positions.

In July 2019, we repaid \$150 million of our revolving loan borrowings using cash from receivables securitization and available cash.

### Cash Flows

The following table sets forth a summary of the net cash provided by (used for) our operating, investing, and financing activities for the six months ended June 30, 2019 and 2018.

	<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
<i>(Dollars in millions)</i>		
Cash (used for) provided by operating activities	\$ (38)	\$ 539
Cash used for investing activities	(256)	(230)
Cash used for financing activities	(283)	(641)

### Operating Activities

We used \$38 million in cash flows for, and received \$539 million in cash flows from our operating activities during the six months ended June 30, 2019 and 2018, respectively. The decrease in cash flows from our operating activities for the six months ended June 30, 2019 was primarily attributable to a decrease in our net income, as well as an increase in our net cash outflows for working capital items due to payments on our accounts payable and certain other accrued liabilities.

*Investing Activities*

We used \$256 million and \$230 million in cash flows for our investing activities during the six months ended June 30, 2019 and 2018, respectively. Our investing cash outflows during the six months ended June 30, 2019 were primarily attributable to \$257 in payments for purchases of property, plant, and equipment. Our investing cash outflows during the six months ended June 30, 2018 were primarily attributable to \$228 million in payments for purchases of property, plant, and equipment, and \$37 million in cash consideration payments for our acquisition of ICOR International, Inc. in April 2018. Our investing cash outflows during the six months ended June 30, 2018 were partially offset by \$41 million in cash proceeds from the sales of assets and businesses, which were primarily attributable to the \$39 million received in connection with our sale of land in Linden, New Jersey.

*Financing Activities*

We used \$283 million and \$641 million in cash flows for our financing activities during the six months ended June 30, 2019 and 2018, respectively. Our financing cash outflows during the six months ended June 30, 2019 were primarily attributable to the following: \$322 million in purchases of our issued and outstanding common stock under our share repurchase program in connection with our capital allocation activities; \$83 million in payments for cash dividends; and, \$30 million in payments for withholding taxes on certain of our vested stock-based compensation awards. These financing cash outflows were partially offset by \$150 million in proceeds from draws on our revolving credit facility, which were used for general corporate purposes. Our financing cash outflows during the six months ended June 30, 2018 were primarily attributable to the following: \$672 million in debt repayments and \$29 million in debt extinguishment payments for “make whole” and early prepayment premiums in connection with our 2018 debt transactions; \$394 million in purchases of our issued and outstanding common stock under our share repurchase program in connection with our capital allocation activities; and, \$61 million in payments for cash dividends. These financing cash outflows were partially offset by \$520 million in proceeds from the issuance of our euro-denominated 4.000% senior unsecured notes due May 2026 in June 2018.

**Current Assets**

The following table sets forth the components of our current assets at June 30, 2019 and December 31, 2018.

<i>(Dollars in millions)</i>	<b>June 30, 2019</b>	<b>December 31, 2018</b>
Cash and cash equivalents	\$ 630	\$ 1,201
Accounts and notes receivable, net	879	861
Inventories	1,250	1,147
Prepaid expenses and other	73	84
<b>Total current assets</b>	<b>\$ 2,832</b>	<b>\$ 3,293</b>

Our accounts and notes receivable, net increased by \$18 million (or 2%) to \$879 million at June 30, 2019, compared with accounts and notes receivable, net of \$861 million at December 31, 2018. The increase in our accounts and notes receivable, net at June 30, 2019 was primarily attributable to the timing of payments from our customers.

Our inventories increased by \$103 million (or 9%) to \$1.3 billion at June 30, 2019, compared with inventories of \$1.1 billion at December 31, 2018. The increase in our inventories at June 30, 2019 was primarily attributable to an increase in our finished products inventories, which resulted from lower net sales volume, and an increase in our raw materials inventories due to the strategic acquisition of ore in our Titanium Technologies segment.

Our prepaid expenses and other assets decreased by \$11 million (or 13%) to \$73 million at June 30, 2019, compared with prepaid expenses and other assets of \$84 million at December 31, 2018. The decrease in our prepaid expenses and other assets at June 30, 2019 was primarily attributable to a decrease in prepaid income tax balances.



**Current Liabilities**

The following table sets forth the components of our current liabilities at June 30, 2019 and December 31, 2018.

*(Dollars in millions)*

	June 30, 2019	December 31, 2018
Accounts payable	\$ 956	\$ 1,137
Current maturities of long-term debt	18	13
Other accrued liabilities	474	559
<b>Total current liabilities</b>	<b>\$ 1,448</b>	<b>\$ 1,709</b>

Our accounts payable decreased by \$181 million (or 16%) to \$956 million at June 30, 2019, compared with accounts payable of \$1.1 billion at December 31, 2018. The decrease in our accounts payable at June 30, 2019 was primarily attributable to the timing of payments to our vendors.

Our current maturities of long-term debt increased by \$5 million (or 38%) to \$18 million at June 30, 2019, compared with current maturities of long-term debt of \$13 million at December 31, 2018. The increase in our current maturities of long-term debt was primarily attributable to the recognition of a \$62 million finance lease liability in the second quarter of 2019.

Our other accrued liabilities decreased by \$85 million (or 15%) to \$474 million at June 30, 2019, compared with other accrued liabilities of \$559 million at December 31, 2018. The decrease in our other accrued liabilities at June 30, 2019 was primarily attributable to lower accrued compensation and employee-related costs, payments of certain accrued expenses, and changes in accrued litigation costs. These decreases were somewhat offset by our recognition of an operating lease liability in connection with our adoption of the new leasing standard on January 1, 2019.

**Credit Facilities and Notes**

See “Note 17 – Debt” to the *Interim Consolidated Financial Statements* and “Note 19 – Debt” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018 for a discussion of our credit facilities and notes.

**Supplier Financing**

We maintain global paying services agreements with several financial institutions. Under these agreements, the financial institutions act as our paying agents with respect to accounts payable due to our suppliers who elect to participate in the program. The agreements allow our suppliers to sell their receivables to one of the participating financial institutions at the discretion of both parties on terms that are negotiated between the supplier and the respective financial institution. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At June 30, 2019 and December 31, 2018, the total payment instructions from us amounted to \$150 million and \$210 million, respectively. Pursuant to their agreement with one of the financial institutions, certain suppliers may elect to be paid early at their discretion. The available capacity under these programs can vary based on the number of investors and/or financial institutions participating in these programs at any point in time.

**Contractual Obligations**

Our contractual obligations at June 30, 2019 did not significantly change from the contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

**Off Balance Sheet Arrangements**

Historically, we have not made significant payments to satisfy guarantee obligations; however, we believe we have the financial resources to satisfy these guarantees in the event required.

**Critical Accounting Policies and Estimates**

Our significant accounting policies are described in our *MD&A* and “Note 3 – Summary of Significant Accounting Policies” to the *Consolidated Financial Statements* in our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no material changes to these critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018, except as described below and in “Note 2 – Recent Accounting Pronouncements” to the *Interim Consolidated Financial Statements*.

## ***Netherlands Pension Plan***

In accordance with the planned restructuring of our Netherlands pension plan (“Plan”), \$935 million of annuity contracts were purchased by the Plan in July 2019 in an amount sufficient to pay off the pension benefits of the Plan’s vested retirees and inactive participants. The Dutch National Bank (“DNB”) has 90 days to approve the transaction as a partial settlement of the Plan, upon which, the insurance company will assume direct and irrevocable responsibility for the payment of pension benefits to the Plan’s vested retirees and inactive participants. The irrevocable transfer of risk will then trigger a partial settlement of the Plan, which we expect will result in a non-cash settlement charge between \$350 million to \$400 million during the third quarter of 2019, most of which is already recorded as a component of our accumulated other comprehensive loss. The purchase of these annuity contracts was fully-funded by the Plan’s investment trust.

## **Recent Accounting Pronouncements**

See “Note 2 – Recent Accounting Pronouncements” to the *Interim Consolidated Financial Statements* for a discussion about recent accounting pronouncements.

## **Environmental Matters**

Consistent with our values and our *Environment, Health, and Safety* policy, we are committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe, and to be good stewards of the environment. We are also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards, and procedures are properly designed to prevent unreasonable risk of harm to people and the environment, and that our handling, manufacture, use, and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

## ***Environmental Remediation***

In large part, because of past operations, operations of predecessor companies, or past disposal practices, we, like many other similar companies, have clean-up responsibilities and associated remediation costs, and are subject to claims by other parties, including claims for matters that are liabilities of DuPont and its subsidiaries that we may be required to indemnify pursuant to the separation-related agreements executed prior to our separation from DuPont.

Our environmental reserve includes estimated costs, including certain accruable costs associated with on-site capital projects, related to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as the Comprehensive Environmental Response Compensation and Liability Act (“CERCLA,” often referred to as “Superfund”), the Resource Conservation and Recovery Act (“RCRA”), and similar federal, state, local, and foreign laws. These laws require certain investigative, remediation, and restoration activities at sites where we conduct or once conducted operations or at sites where our generated waste was disposed. At June 30, 2019 and December 31, 2018, our consolidated balance sheets included environmental remediation liabilities of \$244 million and \$226 million, respectively, relating to these matters, which, as discussed in further detail below, included \$31 million and \$10 million for our Fayetteville, North Carolina facility at June 30, 2019 and December 31, 2018, respectively. In management’s opinion, our environmental remediation liabilities are appropriate based on existing facts and circumstances.

As remediation efforts progress, sites move from the investigation phase (“Investigation”) to the active clean-up phase (“Active Remediation”), and as construction is completed at Active Remediation sites, those sites move to the operation, maintenance, and monitoring (“OM&M”), or closure phase. As final clean-up activities for some significant sites are completed over the next several years, we expect our annual expenses related to these active sites to decline over time. The time frame for a site to go through all phases of remediation (Investigation and Active Remediation) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties (“PRPs”). In addition, for claims that we may be required to indemnify DuPont pursuant to the separation-related agreements, we and DuPont may have limited available information for certain sites or are in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs, and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately \$480 million above the amount accrued at June 30, 2019. In general, uncertainty is greatest and the range of potential liability is widest in the Investigation phase, narrowing over time as regulatory agencies approve site remedial plans. As a result, uncertainty is reduced, and sites ultimately move into OM&M, as needed. As more sites advance from Investigation to Active Remediation to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing OM&M of remedial systems. In addition, portfolio changes, such as an acquisition or divestiture, or notification as a PRP for a multi-party Superfund site, could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position, results of operations, or cash flows for any given year, as such obligation can be satisfied or settled over many years.

**Significant Environmental Remediation Sites**

While there are many remediation sites that contribute to our total accrued environmental remediation liabilities at June 30, 2019 and December 31, 2018, the following table sets forth the sites that are the most significant.

*(Dollars in millions)*

	June 30, 2019	December 31, 2018
Chambers Works, Deepwater, New Jersey	\$ 20	\$ 18
East Chicago, Indiana	20	21
Fayetteville Works, Fayetteville, North Carolina	31	10
Pompton Lakes, New Jersey	43	45
USS Lead, East Chicago, Indiana	14	15
All other sites	116	117
<b>Total accrued environmental remediation</b>	<b>\$ 244</b>	<b>\$ 226</b>

The five sites listed above represented 53% and 48% of our total accrued environmental remediation liabilities at June 30, 2019 and December 31, 2018, respectively. For these five sites, we expect to spend, in the aggregate, \$80 million over the next three years. For all other sites, we expect to spend \$72 million over the next three years.

*Chambers Works, Deepwater, New Jersey*

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, chlorofluorocarbons, and tetraethyl lead. We continue to manufacture a variety of fluorochemicals and finished products at Chambers Works. In addition, three tenants operate processes at Chambers Works including steam/electricity generation, industrial gas production, and the manufacture of intermediate chemicals. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system (“IWS”) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a federal RCRA Corrective Action permit. The site has been studied extensively over the years, and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment. In the fourth quarter of 2017, a site perimeter sheet pile barrier intended to more efficiently contain groundwater was completed.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of various targeted studies on site and in adjacent water bodies to close investigation data gaps, as well as selection and implementation of final remedies under RCRA Corrective Action for various solid waste management units and areas of concern not yet addressed through interim measures.

*East Chicago, Indiana*

East Chicago is a former manufacturing facility we own in East Chicago, Lake County, Indiana. The approximate 440-acre site is bounded to the south by the east branch of the Grand Calumet River, to the east and north by residential and commercial areas, and to the west by industrial areas, including a former lead processing facility. The inorganic chemicals unit on site produced various chloride, ammonia, and zinc products and inorganic agricultural chemicals beginning in 1892 until 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. Current operations, including support activities, now cover 28 acres of the site. The remaining business was sold to W.R. Grace Company (“Grace”) in early 2000, and Grace operates the unit as a tenant. Approximately 172 acres of the site were never developed and are managed by The Nature Conservancy for habitat preservation.

A comprehensive evaluation of soil and groundwater conditions at the site was performed as part of the RCRA Corrective Action process. Studies of historical site impacts began in 1983 in response to preliminary CERCLA actions undertaken by the U.S. Environmental Protection Agency (“EPA”). The EPA eventually issued an Administrative Order on Consent for the site in 1997. The order specified that remediation work be performed under RCRA Corrective Action authority. Work has proceeded under the RCRA Corrective Action process since that time.

Subsequent investigations included the preparation of initial environmental site assessments and multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot long permeable reactive barrier treatment walls were installed along the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA, and the final remedy for the site was issued by the EPA in July 2018.

*Fayetteville Works, Fayetteville, North Carolina*

The Fayetteville Works facility is located 15 miles southeast of the City of Fayetteville in Cumberland and Bladen counties, North Carolina. The facility encompasses approximately 2,200 acres, which were purchased by DuPont in 1970, and are bounded to the east by the Cape Fear River and to the west by North Carolina Highway 87. Currently, the site manufactures plastic sheeting, fluorochemicals, and intermediates for plastics manufacturing. A former manufacturing area, which was sold in 1992, produced nylon strapping and elastomeric tape. DuPont sold its Butacite® and SentryGlas® manufacturing units to Kuraray America, Inc. in June 2014. In July 2015, upon our separation from DuPont, we became the owner of the Fayetteville Works land assets along with fluoromonomers, Nafion® membranes, and the related polymer processing aid manufacturing units. A polyvinyl fluoride resin manufacturing unit remained with DuPont.

Beginning in 1996, several stages of site investigation were conducted under NC DEQ oversight, as required by the facility’s hazardous waste permit. In addition, the site has voluntarily agreed to agency requests for additional investigations of the potential release of “PFAS” (perfluoroalkyl and polyfluoroalkyl substances) beginning with “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) in 2006. As a result of detection of the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid,” sometimes referred to as “GenX” or “C3 Dimer Acid”) in on-site groundwater wells during our investigations in 2017, the NC DEQ issued a Notice of Violation (“NOV”) on September 6, 2017 alleging violations of North Carolina water quality statutes and requiring further response. Since that time, and in response to three additional NOVs issued by NC DEQ, we have worked cooperatively with the agency to investigate and address releases of PFAS to on-site and off-site groundwater and surface water.

As discussed in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*, we and the NC DEQ have filed a final Consent Order that comprehensively addressed various issues, NOVs, and court filings made by the NC DEQ regarding our Fayetteville, North Carolina facility and resolved litigations filed by the NC DEQ and Cape Fear River Watch, a non-profit organization. Of the total estimated liability of \$87 million accrued for this matter at June 30, 2019, \$31 million is included within our overall environmental remediation liabilities, and is related to on-site groundwater and surface water conditions that require further study and clean-up action, and the estimated accruable costs associated with certain on-site capital projects under the final Consent Order.

*Pompton Lakes, New Jersey*

During the 20th century, blasting caps, fuses, and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. The primary contaminants in the soil and sediments are lead and mercury. Groundwater contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection (“NJ DEP”), remedial actions at the site are focused on investigating and cleaning-up the area. Groundwater monitoring at the site is ongoing, and we have installed and continue to install vapor mitigation systems at residences within the groundwater plume. In addition, we are further assessing groundwater conditions. In June 2015, the EPA issued a modification to the site’s RCRA permit that requires us to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project is now complete.

*U.S. Smelter and Lead Refinery, Inc., East Chicago, Indiana*

The U.S. Smelter and Lead Refinery, Inc. (“USS Lead”) Superfund site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal, and residential areas. The primary compounds of interest are lead and arsenic, which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and we are one of a number of parties working cooperatively with the EPA on the safe and timely completion of this work. DuPont’s former East Chicago manufacturing facility was located adjacent to the site, and DuPont assigned responsibility for the site to us in the separation agreement.

The USS Lead Superfund site was listed on the National Priorities List in 2009. To facilitate negotiations with PRPs, the EPA divided the residential part of the USS Lead Superfund site into three zones, referred to as Zone 1, Zone 2, and Zone 3. The division into three zones resulted in Atlantic Richfield Co. (“Atlantic Richfield”) and DuPont entering into an agreement in 2014 with the EPA and the State of Indiana to reimburse the EPA’s costs to implement clean-up in Zone 1 and Zone 3. More recently, in March 2017, we and three other parties – Atlantic Richfield, DuPont, and the U.S. Metals Refining Co. (“U.S. Metals”) – entered into an administrative order on consent to reimburse the EPA’s costs to clean-up a portion of Zone 2. In March 2018, the EPA issued a Unilateral Administrative Order for the remainder of the Zone 2 work to five parties, including us, Atlantic Richfield, DuPont, U.S. Metals, and USS Lead Muller Group, and these parties have entered into an interim allocation agreement to complete that work by the end of 2019. There is uncertainty as to whether these parties will be able to agree on a final allocation for Zone 2 and/or the other Zones, and whether any additional PRPs may be identified.

The environmental accrual for USS Lead continues to be based on the 2012 Record of Decision (“ROD”) and Statement of Work for Zone 1 and the associated portion of Zone 3 not yet completed, as well as the current estimate of our share of remaining Zone 2 clean-up. The EPA released a proposed amendment to the 2012 ROD for a portion of Zone 1 in December 2018 (following its August 2018 Feasibility Study Addendum), with its recommended option based on future residential use. However, the proposed amendment was sent out for public comment with the EPA’s statement that the remedy basis and cost may change based on community input on future land use. The EPA’s final decision was expected sometime in the first half of 2019, but has not yet been released. We expect that our future costs for Zone 1 will be contingent on this remedy decision, as well as any final allocation between PRPs. Most recently, we and other PRPs received documentation from the EPA of past response costs and other unreimbursed direct costs incurred by the EPA in managing the site dating back at least a decade. We have reviewed and evaluated this documentation with respect to our current legal obligations and likely future allocation. As a result of this review, we have recorded an additional accrual for \$4 million in the second quarter of 2019.

***New Jersey Department of Environmental Protection Directives and Litigation***

In March 2019, the NJ DEP issued two Directives and filed four lawsuits against Chemours and other defendants. Further discussion related to these matters is included in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

**PFOA**

See our discussion under the heading “PFOA” in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

**GenX**

On June 26, 2019 the Member States Committee of the European Chemicals Agency (“ECHA”) voted to list HFPO Dimer Acid as a Substance of Very High Concern. The vote was based on Article 57(f) – equivalent level of concern having probable serious effects to the environment. This identification does not impose immediate regulatory restriction or obligations, but may lead to a future authorization or restriction of the substance.

**Delaware Chancery Court Lawsuit**

In May 2019, we filed a lawsuit in Delaware Chancery Court (“Chancery Court”) against DowDuPont, Inc., Corteva, Inc., and DuPont concerning DuPont’s contention that it is entitled to unlimited indemnity from us for specified liabilities that DuPont assigned to us in the spin-off. The lawsuit requests that the Chancery Court enter a declaratory judgment limiting DuPont’s indemnification rights against us and the transfer of liabilities to us to the actual “high-end maximum realistic exposures” it stated in connection with the spin-off, or, in the alternative, requiring the return of the approximate \$4 billion dividend DuPont extracted from us in connection with the spin-off. In response, DuPont has filed a Motion to Dismiss the lawsuit seeking to have the dispute heard in a non-public arbitration rather than the Chancery Court. Many of the potential litigation liabilities discussed in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements* are at issue in the lawsuit.

## Non-GAAP Financial Measures

We prepare our interim consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”). To supplement our financial information presented in accordance with GAAP, we provide the following non-GAAP financial measures – Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share (“EPS”), Free Cash Flows (“FCF”), and Return on Invested Capital (“ROIC”) – in order to clarify and provide investors with a better understanding of our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision-making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our CODM.

Adjusted EBITDA is defined as income (loss) before income taxes, excluding the following:

- interest expense, depreciation, and amortization;
- non-operating pension and other post-retirement employee benefit costs, which represents the components of net periodic pension (income) costs excluding the service cost component;
- exchange (gains) losses included in other income (expense), net;
- restructuring, asset-related, and other charges;
- asset impairments;
- (gains) losses on sales of business or assets; and,
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

Adjusted Net Income is defined as our net income or loss, adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Adjusted EPS is presented on a diluted basis and is calculated by dividing Adjusted Net Income by the weighted-average number of our common shares outstanding, accounting for the dilutive impact of our stock-based compensation awards. FCF is defined as our cash flows provided by (used for) operating activities, less purchases of property, plant, and equipment as shown in our consolidated statements of cash flows. ROIC is defined as Adjusted Earnings before Interest and Taxes (“EBIT”), divided by the average of our invested capital, which amounts to our net debt, plus equity.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing our operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, FCF, and ROIC should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the *Interim Consolidated Financial Statements* and notes thereto included in this report, as well as the *Consolidated Financial Statements* and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018.

The Chemours Company

The following table sets forth a reconciliation of Adjusted EBITDA, Adjusted Net Income, and Adjusted EPS to our net income attributable to Chemours for the three and six months ended June 30, 2019 and 2018.

<i>(Dollars in millions, except per share amounts)</i>	Three Months Ended June 30,		Six Months Ended June 30,	
	2019	2018	2019	2018
<b>Net income attributable to Chemours</b>	\$ 96	\$ 281	\$ 189	\$ 578
Non-operating pension and other post-retirement employee benefit income	(3)	(7)	(6)	(14)
Exchange losses (gains), net	9	(2)	3	(2)
Restructuring, asset-related, and other charges (1)	7	10	15	20
Loss on extinguishment of debt	—	38	—	38
Gain on sales of assets and businesses (2)	(2)	(3)	(2)	(45)
Transaction costs	1	9	1	9
Legal charges (3)	8	10	38	14
Adjustments made to income taxes (4)	7	(8)	1	(13)
Benefit from income taxes relating to reconciling items (5)	(3)	(14)	(11)	(5)
<b>Adjusted Net Income</b>	<b>120</b>	<b>314</b>	<b>228</b>	<b>580</b>
<b>Net income attributable to non-controlling interests</b>	<b>—</b>	<b>1</b>	<b>—</b>	<b>1</b>
Interest expense, net	52	48	103	100
Depreciation and amortization	78	71	154	141
All remaining provision for income taxes	33	63	60	143
<b>Adjusted EBITDA</b>	<b>\$ 283</b>	<b>\$ 497</b>	<b>\$ 545</b>	<b>\$ 965</b>
Weighted-average number of common shares outstanding - basic	164,118,816	177,798,484	165,982,289	179,922,433
Dilutive effect of our employee compensation plans	2,822,810	6,022,757	3,508,621	6,142,986
Weighted-average number of common shares outstanding - diluted	166,941,626	183,821,241	169,490,910	186,065,419
<b>Per share data</b>				
Basic earnings per share of common stock	\$ 0.58	\$ 1.58	\$ 1.14	\$ 3.21
Diluted earnings per share of common stock	0.57	1.53	1.12	3.11
Adjusted basic earnings per share of common stock	0.73	1.77	1.38	3.22
Adjusted diluted earnings per share of common stock	0.72	1.71	1.35	3.12

(1) Includes restructuring, asset-related, and other charges, which are discussed in further detail in "Note 5 – Restructuring, Asset-related, and Other Charges" to the *Interim Consolidated Financial Statements*.

(2) For the six months ended June 30, 2018, gain on sales of assets and businesses included a \$42 million gain associated with the sale of our Linden, New Jersey site.

(3) Includes litigation settlements, PFOA drinking water treatment accruals, and other legal charges. For the three and six months ended June 30, 2019, legal charges included \$7 million and \$34 million in additional charges for the approved final Consent Order associated with certain matters at our Fayetteville, North Carolina facility, which are discussed in further detail in "Note 19 – Commitments and Contingent Liabilities" to the *Interim Consolidated Financial Statements*.

(4) Includes the removal of certain discrete income tax impacts within our provision for income taxes, such as the benefit from windfalls on our share-based payments, historical valuation allowance adjustments, unrealized gains and losses on foreign exchange rate changes, and other discrete income tax items.

(5) The income tax impacts included in this caption are determined using the applicable rates in the taxing jurisdictions in which income or expense occurred and represents both current and deferred income tax expense or benefit based on the nature of the non-GAAP financial measure.

## The Chemours Company

The following table sets forth a reconciliation of FCF to our cash flows provided by operating activities for the six months ended June 30, 2019 and 2018.

<i>(Dollars in millions)</i>	<b>Six Months Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
Cash flows (used for) provided by operating activities	\$ (38)	\$ 539
Less: Purchases of property, plant, and equipment	(257)	(228)
<b>Free Cash Flows</b>	<b>\$ (295)</b>	<b>\$ 311</b>

The following table sets forth a reconciliation of invested capital, net, a component of ROIC, to our total debt, equity, and cash and cash equivalents at June 30, 2019 and 2018.

<i>(Dollars in millions)</i>	<b>Period Ended June 30,</b>	
	<b>2019</b>	<b>2018</b>
Adjusted EBITDA (1)	\$ 1,321	\$ 1,740
Less: Depreciation and amortization (1)	(296)	(273)
<b>Adjusted EBIT</b>	<b>1,025</b>	<b>1,467</b>
Total debt	4,208	3,973
Total equity	829	1,025
Less: Cash and cash equivalents	(630)	(1,217)
<b>Invested capital, net</b>	<b>\$ 4,407</b>	<b>\$ 3,781</b>
Average invested capital (2)	\$ 3,989	\$ 3,481
<b>Return on Invested Capital</b>	<b>25.7%</b>	<b>42.1%</b>

(1) Based on amounts for the trailing 12 months ended June 30, 2019 and 2018. Reconciliations of Adjusted EBITDA to net income attributable to Chemours are provided on a quarterly basis. See the preceding table for the reconciliation of Adjusted EBITDA to net income attributable to Chemours for the three and six months ended June 30, 2019 and 2018.

(2) Average invested capital is based on a five-quarter trailing average of invested capital, net.



### Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities, and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on our future cash flows and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

By using derivative financial instruments, we are subject to credit and market risk. The fair values of the derivative financial instruments are determined by using valuation models whose inputs are derived using market observable inputs, and reflects the asset or liability position as of the end of each reporting period. When the fair value of a derivative contract is positive, the counterparty owes us, thus creating a receivable risk for us. We are exposed to counterparty credit risk in the event of non-performance by counterparties to our derivative agreements. We minimize counterparty credit (or repayment) risk by entering into transactions with major financial institutions of investment grade credit ratings.

#### Foreign Currency Risks

We enter into foreign currency forward contracts to minimize the volatility in our earnings related to foreign exchange gains and losses resulting from remeasuring our monetary assets and liabilities that are denominated in non-functional currencies, and any gains and losses from the foreign currency forward contracts are intended to be offset by any gains or losses from the remeasurement of the underlying monetary assets and liabilities. These derivatives are stand-alone and, except as described below, have not been designated as a hedge. At June 30, 2019, we had 14 foreign currency forward contracts outstanding, with an aggregate gross notional U.S. dollar equivalent of \$425 million, the fair value of which amounted to a \$1 million net loss. At December 31, 2018, we had 20 foreign currency forward contracts outstanding, with an aggregate gross notional U.S. dollar equivalent of \$503 million, the fair value of which amounted to less than \$1 million. We recognized a net gain of \$1 million and a net loss of \$1 million for the three and six months ended June 30, 2019, respectively, and net losses of \$8 million and \$5 million for the three and six months ended June 30, 2018, respectively, within other income, net related to our non-designated foreign currency forward contracts.

We enter certain qualifying foreign currency forward contracts under a cash flow hedge program to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of our international subsidiaries that use the euro as their functional currency. At June 30, 2019, we had 123 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of \$137 million, the fair value of which amounted to \$1 million of net unrealized gain. At December 31, 2018, we had 75 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of \$143 million, the fair value of which amounted to \$3 million of net unrealized gain. We recognized a pre-tax gain of \$2 million for the six months ended June 30, 2019, and pre-tax gains of \$7 million for the three and six months ended June 30, 2018, on our cash flow hedge within accumulated other comprehensive loss. For the three and six months ended June 30, 2019, \$3 million and \$6 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively. No amounts were reclassified to cost of goods sold from accumulated other comprehensive loss during the three and six months ended June 30, 2018.

We designated our euro-denominated debt as a hedge of our net investment in certain of our international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders' equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar. We recognized a pre-tax loss of \$7 million and a pre-tax gain of \$3 million for the three and six months ended June 30, 2019, respectively, and pre-tax gains of \$48 million and \$13 million for the three and six months ended June 30, 2018, respectively, on our net investment hedge within accumulated other comprehensive loss.

Our risk management programs and the underlying exposures are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the changes in the value of the underlying exposures. See "Note 22 – Financial Instruments" to the *Interim Consolidated Financial Statements* for further information.

**Item 4. CONTROLS AND PROCEDURES**

**Disclosure Controls and Procedures**

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission (“SEC”). These controls and procedures also provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), to allow timely decisions regarding required disclosures.

As of June 30, 2019, our CEO and CFO, together with management, conducted an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

**Changes in Internal Control over Financial Reporting**

There have been no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

## Item 1. LEGAL PROCEEDINGS

Legal Proceedings

We are subject to various legal proceedings, including, but not limited to, product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. Information regarding certain of these matters is set forth below and in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

Litigation**PFOA: Environmental and Litigation Proceedings**

For purposes of this report, the term “PFOA” means, collectively, perfluorooctanoic acid and its salts, including the ammonium salt, and does not distinguish between the two forms. Information related to this and other litigation matters is included in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

**Fayetteville, North Carolina**

The following actions related to Fayetteville, North Carolina, as discussed in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*, are filed in the U.S. District Court for the Eastern District of North Carolina, Southern Division:

- *Carey et al. vs. E. I. DuPont de Nemours and Company* (7:17-cv-00189-D; 7:17-cv-00197-D; and, 7:17-cv-00201-D);
- *Cape Fear Public Utility Authority vs. The Chemours Company FC, LLC et al. and Brunswick County v. DowDuPont et al.* (7:17-cv-00195-D and 7:17-cv-00209-D); and,
- *Dew et al. vs. E. I. DuPont de Nemours and Company et al.* (17:18-cv-00030-D).

Environmental Proceedings**LaPorte Plant, LaPorte, Texas**

The U.S. Environmental Protection Agency (“EPA”) conducted a multimedia inspection at the DuPont LaPorte, Texas facility in January 2008. DuPont, the EPA, and the U.S. Department of Justice began discussions in the fall of 2011 relating to the management of certain materials in the facility’s waste water treatment system, hazardous waste management, flare, and air emissions. These negotiations continue. We operate a fluoroproducts production facility at this site.

**Dordrecht, Netherlands**

We have complied with requests from the local environmental agency (“DCMR,” formerly under the jurisdiction of “OZHZ”), the Labor Inspectorate (“iSZW”), the Inspectorate for Environment and Transportation (“ILT”), and the Water Authority (“RWS”) in the Netherlands for information and documents regarding the Dordrecht site’s operations. We have complied with the requests, and the agencies have published several reports between 2016 and 2018, all of them publicly-available. The National Institute for Public Health and the Environment (“RIVM”) has also published several reports with respect to PFOA and the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid,” sometimes referred to as “GenX” or “C3 Dimer Acid”). In December 2018, DCMR imposed a €1 million fine after undertaking waste water tests, which detected low levels of PFOA. DCMR continued taking samples and has imposed three additional fines between January and May 2019, each of which was €0.25 million. We have appealed all the fines and we believe that we have valid defenses to prevail. We continue to cooperate with all authorities in responding to information requests.

Fayetteville, North Carolina

In February 2019, we received a Notice of Violation (“NOV”) from the EPA alleging certain Toxic Substances Control Act violations at our Fayetteville, North Carolina site. Matters raised in the NOV could have the potential to affect operations at the Fayetteville site. We responded to the EPA in March 2019 asserting that we have not violated environmental laws. At this time, management does not believe that a loss is probable related to the matters in this NOV. Further discussion related to this matter is included in “Note 19 – Commitments and Contingent Liabilities” to the *Interim Consolidated Financial Statements*.

**Item 1A. RISK FACTORS**

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.

**Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

**Issuer Purchases of Equity Securities**

**2018 Share Repurchase Program**

On August 1, 2018, our board of directors approved a share repurchase program authorizing the purchase of shares of our issued and outstanding common stock in an aggregate amount not to exceed \$750 million, plus any associated fees or costs in connection with our share repurchase activity (“2018 Share Repurchase Program”). On February 13, 2019, our board of directors increased the authorization amount of the 2018 Share Repurchase Program from \$750 million to \$1.0 billion. Under the 2018 Share Repurchase Program, shares of our common stock can be purchased on the open market from time to time, subject to management’s discretion, as well as general business and market conditions. Our 2018 Share Repurchase Program became effective on August 1, 2018, was announced to the public on August 2, 2018, and will continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

The following table sets forth the purchases of our issued and outstanding common stock under the 2018 Share Repurchase Program for the three months ended June 30, 2019.

*(Dollars in millions, except per share amounts)*

<b>Period</b>	<b>Total Number of Shares Purchased (1)</b>	<b>Average Price Paid per Share (2)</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</b>	<b>Approximate Dollar Value of Shares That May Yet be Purchased Under the Plans or Programs (2)</b>
Month ended April 30, 2019	1,387,241	\$ 38.51	1,387,241	\$ 436
Month ended May 31, 2019	229,899	34.44	229,899	428
Month ended June 30, 2019	—	—	—	—
<b>Total</b>	<b>1,617,140</b>	<b>\$ 37.93</b>	<b>1,617,140</b>	<b>\$ 428</b>

(1) The total number of shares purchased under the share repurchase program is determined using trade dates for the related transactions.

(2) The average price paid per share and approximate dollar value of shares that may yet be purchased under the share repurchase program exclude fees, commissions, and other charges for the related transactions.

As of June 30, 2019, we have purchased a cumulative 15,245,999 shares of our issued and outstanding common stock under the share repurchase program, which amounted to \$572 million at an average share price of \$37.52 per share. The aggregate amount of our common stock that remained available for repurchase at June 30, 2019 was \$428 million.

**Item 3. DEFAULTS UPON SENIOR SECURITIES**

None.

**Item 4. MINE SAFETY DISCLOSURES**

Information regarding mine safety and other regulatory actions at the Company’s surface mine in Starke, Florida is included in *Exhibit 95* to this Quarterly Report on Form 10-Q.

**Item 5. OTHER INFORMATION**

None.

**Item 6. EXHIBITS**

Exhibit Number	Description
3.1	<a href="#"><u>Company’s Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).</u></a>
3.2	<a href="#"><u>Company’s Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).</u></a>
31.1	<a href="#"><u>Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Executive Officer.</u></a>
31.2	<a href="#"><u>Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Financial Officer.</u></a>
32.1	<a href="#"><u>Section 1350 Certification of the Company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.</u></a>
32.2	<a href="#"><u>Section 1350 Certification of the Company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.</u></a>
95	<a href="#"><u>Mine Safety Disclosures</u></a>
101	The following financial statements from the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2019 have been formatted in Inline XBRL: (i) the Interim Consolidated Statements of Operations (Unaudited); (ii) the Interim Consolidated Statements of Comprehensive Income (Unaudited); (iii) the Interim Consolidated Balance Sheets; (iv) the Interim Consolidated Statements of Stockholders’ Equity (Unaudited); (v) the Interim Consolidated Statements of Cash Flows (Unaudited); and, (vi) the Notes to the Interim Consolidated Financial Statements (Unaudited). These financial statements have been tagged as blocks of text, and include detailed tags.
104	The cover page from the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2019, which has been formatted in Inline XBRL.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

THE CHEMOURS COMPANY  
(Registrant)

Date: August 2, 2019

By: /s/ Sameer Ralhan

Sameer Ralhan  
Senior Vice President, Chief Financial Officer and Treasurer  
(As Duly Authorized Officer and Principal Financial Officer)

## CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Mark P. Vergnano, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Chemours Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 2, 2019

By: /s/ Mark P. Vergnano

Mark P. Vergnano  
President and Chief Executive Officer

## CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Sameer Ralhan, certify that:

1. I have reviewed this quarterly report on Form 10-Q of The Chemours Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 2, 2019

By: /s/ Sameer Ralhan

Sameer Ralhan  
Senior Vice President, Chief Financial  
Officer and Treasurer



**Certification of CEO Pursuant to  
18 U.S.C. Section 1350,  
As Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of The Chemours Company (the "Company") on Form 10-Q for the period ended June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark P. Vergnano, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Mark P. Vergnano

---

Mark P. Vergnano  
President and Chief Executive Officer  
August 2, 2019

**Certification of CFO Pursuant to  
18 U.S.C. Section 1350,  
As Adopted Pursuant to  
Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report of The Chemours Company (the "Company") on Form 10-Q for the period ended June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Sameer Ralhan, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Sameer Ralhan

---

Sameer Ralhan  
Senior Vice President, Chief Financial  
Officer and Treasurer  
August 2, 2019

MINE SAFETY DISCLOSURES

The company owns and operates a surface mine near Starke, Florida. The following table provides information about citations, orders and notices issued from the Mine Safety and Health Administration (“MSHA”) under the Federal Mine Safety and Health Act of 1977 (“Mine Act”) for the quarter ended June 30, 2019.

Mine Identification Number	Section 104 S&S1 Citations (#)	Section 104(b) Orders (#)	Section 104(d) Citations and Orders (#)	Section 110(b)(2) Violations (#)	Section 107(a) Orders (#)	Total Dollar Value of MSHA Assessments Proposed (\$)	Total Number of Mining Related Fatalities (#)	Received Notice of Pattern of Violations Under Section 104(e) (yes/no)	Received Notice of Potential to Have Pattern Under Section 104(e) (yes/no)	Legal Actions Pending as of Last Day of Period (#)	Legal Actions Initiated During Period (#)	Legal Actions Resolved During Period (#)
Starke, FL (0800225)	*	—	—	—	—	\$ —	—	No	No	—	—	—

1 S&S refers to significant and substantial violations of mandatory health or safety standards under section 104 of the Mine Act.  
 \* No MSHA citations, orders, or notices were received during the quarter ended June 30, 2019.